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Global, regional, and national comparative risk assessment of 79 
behavioural, environmental and occupational, and metabolic 
risks or clusters of risks in 188 countries, 1990–2013: a 
systematic analysis for the Global Burden of Disease Study 2013
GBD 2013 Risk Factors Collaborators*
Summary
Background—The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) 
is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of 
modifiable risk factors, can help to identify emerging threats to population health and 
opportunities for prevention. The GBD 2013 provides a timely opportunity to update the 
comparative risk assessment with new data for exposure, relative risks, and evidence on the 
appropriate counterfactual risk distribution.
Methods—Attributable deaths, years of life lost, years lived with disability, and disability-
adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 
2010 methods. Risk–outcome pairs meeting explicit evidence criteria were assessed for 188 
countries for the period 1990–2013 by age and sex using three inputs: risk exposure, relative risks, 
and the theoretical minimum risk exposure level (TMREL). Risks are organised into a hierarchy 
with blocks of behavioural, environmental and occupational, and metabolic risks at the first level 
of the hierarchy. The next level in the hierarchy includes nine clusters of related risks and two 
individual risks, with more detail provided at levels 3 and 4 of the hierarchy. Compared with GBD 
2010, six new risk factors have been added: handwashing practices, occupational exposure to 
trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration 
rate. For most risks, data for exposure were synthesised with a Bayesian meta-regression method, 
DisMod-MR 2.0, or spatial-temporal Gaussian process regression. Relative risks were based on 
meta-regressions of published cohort and intervention studies. Attributable burden for clusters of 
risks and all risks combined took into account evidence on the mediation of some risks such as 
high body-mass index (BMI) through other risks such as high systolic blood pressure and high 
cholesterol.
Findings—All risks combined account for 57·2% (95% uncertainty interval [UI] 55·8–58·5) of 
deaths and 41·6% (40·1–43·0) of DALYs. Risks quantified account for 87·9% (86·5–89·3) of 
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cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected 
tropical diseases and malaria. In terms of global DALYs in 2013, six risks or clusters of risks each 
caused more than 5% of DALYs: dietary risks accounting for 11·3 million deaths and 241·4 
million DALYs, high systolic blood pressure for 10·4 million deaths and 208·1 million DALYs, 
child and maternal malnutrition for 1·7 million deaths and 176·9 million DALYs, tobacco smoke 
for 6·1 million deaths and 143·5 million DALYs, air pollution for 5·5 million deaths and 141·5 
million DALYs, and high BMI for 4·4 million deaths and 134·0 million DALYs. Risk factor 
patterns vary across regions and countries and with time. In sub-Saharan Africa, the leading risk 
factors are child and maternal malnutrition, unsafe sex, and unsafe water, sanitation, and 
handwashing. In women, in nearly all countries in the Americas, north Africa, and the Middle 
East, and in many other high-income countries, high BMI is the leading risk factor, with high 
systolic blood pressure as the leading risk in most of Central and Eastern Europe and south and 
east Asia. For men, high systolic blood pressure or tobacco use are the leading risks in nearly all 
high-income countries, in north Africa and the Middle East, Europe, and Asia. For men and 
women, unsafe sex is the leading risk in a corridor from Kenya to South Africa.
Interpretation—Behavioural, environmental and occupational, and metabolic risks can explain 
half of global mortality and more than one-third of global DALYs providing many opportunities 
for prevention. Of the larger risks, the attributable burden of high BMI has increased in the past 23 
years. In view of the prominence of behavioural risk factors, behavioural and social science 
research on interventions for these risks should be strengthened. Many prevention and primary 
care policy options are available now to act on key risks.
Funding—Bill & Melinda Gates Foundation.
Introduction
The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first 
of a series of annual updates of the GBD. Quantification of functional health loss and 
mortality by disease and injury is an important input to more informed health policy, as is 
the contribution of different risk factors to patterns of disease and injury across countries. 
Risk factor quantification, particularly for modifiable risk factors, can help to identify 
emerging threats to population health and opportunities for prevention.
The Global Burden of Disease study 2010 (GBD 2010) provided the most comprehensive 
comparative assessment of risk factors covering 67 risk factors or clusters of risks for 21 
regions from 1990 to 2010.1 The GBD comparative risk assessment (CRA) brings together 
data for excess mortality and disability associated with risk factors, data for exposure to 
risks, and evidence-based assumptions on the desired counterfactual distribution of risk 
exposure to estimate how much of the burden observed in a given year can be attributed to 
risk exposure in that year and in all previous years. GBD 2010 generated broad interest in 
the scientific community and public health agencies.2–4 GBD 2010 also generated several 
scientific debates on topics such as the magnitude of burden related to diet, the low 
estimates of burden related to unsafe water and sanitation, and exclusion of some risk–
outcome pairs from the analysis.2,5–10 Additionally, new studies have been published since 
the release of GBD 2010 that inform both estimates of relative risks and exposure in 
different countries.11–15
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The GBD 2013 provides a timely opportunity to update each aspect of the CRA with new 
data for exposure, add new risk–outcome pairs meeting study inclusion criteria, and 
incorporate new data for relative risks and the appropriate counterfactual risk distribution. 
Important insights from scientific debates on GBD 2010 have been used in revised 
approaches. This analysis supersedes all previous GBD CRA results by providing a 
complete revised time-series of attributable burden from 1990 to 2013, for 188 countries, 
with consistent definitions and methods. This CRA also allows us to explore how much of 
the burden of disease around the world is not explained by the behavioural, environmental 
and occupational, and metabolic risks included in this study.
Methods
Overview
In general, this analysis follows the CRA methods used in GBD 2010.1 Conceptually, the 
CRA approach evaluates how much of the burden of disease observed in a given year can be 
attributed to past exposure to a risk. Attributable burden is estimated by comparing observed 
health outcomes to those that would have been observed if a counterfactual level of 
exposure had occurred in the past. Given that different risks lead to different health 
outcomes, assessments are undertaken separately for specific risk–outcome pairs.
For most risk–outcome pairs, we estimated the attributable burden using the following 
equations.
Where ABjasct is the attributable burden for risk factor j in age group a, sex s, country c and 
year t. DALYoasct is disability-adjusted life-years (DALYs) for cause o (of w relevant 
outcomes for risk factor j) in age group a, sex s, country c and year t. PAFjoasct is the 
population attributable fraction (PAF) for cause o due to risk factor j in age group a, sex s, 
country c and year t. Attributable deaths, years of life lost (YLLs), or years lived with 
disability (YLDs) are computed by substituting in the equation these metrics for DALYs.
Risks fall into three categories on the basis of how exposure is measured: dichotomous, 
polytomous, and continuous. High systolic blood pressure is an example of a risk measured 
on a continuous scale. The PAFjoasct for a continuous risk factor in each country is defined 
as:16
RRjoasc (x) is the relative risk as a function of exposure level x for risk factor j, cause o, age-
group a, sex s, and country c. l is the lowest level of exposure and u is the highest level of 
exposure observed. Pjasct (x) is the distribution of exposure for risk j in age-group a, sex s, 
country c, and year t. TMRELjas is the theoretical minimum risk exposure level for risk 
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factor j, age group a, and sex s. The discrete version of this equation for polytomous and 
dichotomous risks is provided in the appendix (p 2).
The equations highlight the four key components by cause, age, sex, country, and year that 
go into estimations of the burden attributable to a risk factor: the number of deaths, YLLs, 
YLDs, or DALYs; exposure levels for a risk factor; relative risk of a given outcome due to 
exposure; and the counterfactual level of risk factor exposure. In the CRA approach, the 
counterfactual level of risk exposure is selected to be the risk exposure that is theoretically 
possible and minimises overall risk (theoretical minimum risk exposure level [TMREL]).17 
The intention is to quantify how much disease burden could be lowered by shifting the 
distribution of a risk to the level that would lead to the greatest improvement in population 
health. GBD 2013 provides the rates of mortality, YLLs, YLDs, and DALYs by cause.18,19 
We focus here on the data and methods used to estimate 79 behavioural, environmental and 
occupational, and metabolic risks and clusters of these risks, levels of exposure, relative 
risks, and the choice of TMREL (a more detailed presentation of methods is provided in 
appendix [pp 2–23]).
Risk–outcome pairs and risk factor hierarchy
In this analysis, we focus on three groups of risk factors: behavioural, environmental and 
occupational, and metabolic. Figure 1 shows a more complete causal web (not all the arrows 
detailing possible interconnections have been drawn) that recognises the role of four other 
sets of risks: genes; the microbiome and other host factors; public health and medical care 
interventions; and social, economic, and cultural factors. It is currently beyond the scope of 
this study to quantify these other categories of risks or causes; however, in future iterations 
of the GBD we intend to broaden the analysis to include at least some of these broader 
causes.
For the current assessment focused on behavioural, environmental and occupational, and 
metabolic risk factors, risk–outcome pairs have been included based on four criteria. These 
criteria take into account the importance of each risk factor to either disease burden, policy, 
or both; the availability of sufficient data to estimate risk factor exposure; evidence from 
epidemiological studies supporting a causal relation between risk factor exposure and the 
outcome and available data to estimate effect sizes per unit of exposure increase; and 
evidence that these effects can be applied to a general population. Following GBD 2010, we 
have adopted the World Cancer Research Fund grading of evidence supporting the causal 
relation between risk factor exposure and an outcome. They defined four levels of evidence: 
convincing, probable, possible, and insufficient. Only risk–outcome pairs judged to meet the 
criteria of convincing or probable were included. Convincing evidence is defined as 
“evidence based on epidemiological studies showing consistent associations between 
exposure and disease, with little or no evidence to the contrary. The available evidence is 
based on a substantial number of studies including prospective observational studies and 
where relevant, randomised controlled trials of sufficient size, duration, and quality showing 
consistent effects. The association should be biologically plausible.” Probable evidence is 
defined as “evidence based on epidemiological studies showing fairly consistent 
associations between exposure and disease, but for which there are perceived shortcomings 
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in the available evidence or some evidence to the contrary, which precludes a more definite 
judgment. Shortcomings in the evidence may be any of the following: insufficient duration 
of trials (or studies); insufficient trials (or studies) available; inadequate sample sizes; or 
incomplete follow-up. Laboratory evidence is usually supportive. The association should be 
biologically plausible.”
Table 1 summarises the included risk factors; there are, counting risks and clusters of risks, 
79 different risks in the hierarchy, including 13 level 2 groupings of risk factors and 63 
individual risks. We have quantified the burden of each of the level 1, level 2, and level 3 
groupings and an overall estimate of all risk factors combined. Risks are organised into a 
hierarchy with blocks of behavioural, environmental and occupational, and metabolic risks 
at the first level of the hierarchy. The next level in the hierarchy includes nine clusters of 
related risks and two individual risks, with more detail provided at levels 3 and 4 of the 
hierarchy. New risk–outcome pairs were added for risks already included in GBD 2010 due 
to new evidence, and some risk–outcome pairs were excluded because they did not meet the 
quality of evidence criteria.
Estimating risk factor exposure
Data and exposure categories—For each risk factor exposure, we began with the GBD 
2010 sources and supplemented those by identifying and using published studies through 
systematic reviews of the literature, household survey data, census data, and satellite data 
(used for PM2·5 estimation). Our analyses for the GBD 2013 of tobacco smoking prevalence 
and obesity have been published.20,21 For some risks such as diet and alcohol consumption, 
we have also used administrative record systems. Appendix pp 88–475 provides citations for 
all sources used for estimating risk factor exposure organised by country.
We have computed a data representativeness index (DRI) for risk factor exposure 
estimation. The DRI for a risk factor is the fraction of countries for which we have identified 
any data for the risk factor. Table 1 also provides the DRI for the entire period 1985–2013 
and the DRI calculated for three intervals: pre-1997, 1998–2005, and from 2006 to 2013. 
The overall DRI ranges from 17% for diet low in polyunsaturated fatty acids to 100% for 
ambient ozone pollution and ambient particulate matter pollution. The DRI for PM2·5 is 
100% because data are available for all countries and all years, although direct satellite 
observations are unavailable before 1998.
Modelling strategies for exposure levels—Appendix pp 49–51 lists the modelling 
strategy used to estimate exposure for every risk factor. For 23 risks, we used DisMod-MR 
2.0, which is a Bayesian meta-regression method used extensively in estimating the 
prevalence of diseases for GBD 2013. See Vos and colleagues19 for a detailed description of 
the likelihood used for estimation and an explanation of improvements in DisMod-MR 2.0 
compared with DisMod-MR 1.0, used in GBD 2010. In brief, DisMod-MR 2.0 shows 
improvements over DisMod-MR 1.0 in computational speed, geographical disaggregation, 
and display capabilities. The advantage of DisMod-MR 2.0 is that it estimates both the age–
sex pattern of a risk as well as different levels over time based on estimation for 1990, 1995, 
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2000, 2005, 2010, and 2013. For 12 risk factors modelled with DisMod-MR 2.0, we 
conducted cross-validation tests (appendix pp 476–78).
For 34 risks, we used spatiotemporal Gaussian process regression (ST-GPR), which was 
also used for multiple risk factors in GBD 2010.21 ST-GPR has been used for risk factors for 
which the data density is sufficient to estimate a very flexible time trend that does not vary 
over age. If the tabulated data were in standard age groups or at the household level, such as 
access to different levels of improved water and sanitation, exposure to radon, or available 
zinc intake, we used ST-GPR; but if the data were available by different age intervals or 
mixed sex groups, we used DisMod-MR 2.0 because of its ability to integrate over age and 
adjust for different exposure definitions in the data.
For PM2·5, estimates of annual concentrations were generated by combining data from 
atmospheric chemistry transport models and satellite retrievals of aerosols in the 
atmosphere.22 The combined PM2·5 concentrations were then calibrated against 
observations from ground-level monitoring of particles from more than 75 countries. For 
modelling the burden attributable to tobacco smoking, we used the smoking impact ratio 
(SIR) developed by Peto, Lopez, and colleagues23 for cancers and chronic respiratory 
disease, and 5-year lagged smoking prevalence for all cardiovascular outcomes, 
tuberculosis, diabetes, and asthma. The SIR is used to reflect past exposure, duration, and 
intensity of smoking in a population.23 Alcohol exposure estimation used both 
administrative and survey data to estimate levels of abstainers, former drinkers, binge 
drinkers, and drinks per day for regular drinkers. Physical activity exposure was modelled in 
terms of four categories of metabolic equivalent (MET) min per week (ratio of metabolic 
rate during a specific physical activity to a resting metabolic rate): inactivity, less than 600 
MET min per week; low activity, 600–3999; moderate activity, 4000–7999; and high 
activity, greater than 8000. Exposure to occupational risks was estimated with data from 
labour force surveys and censuses on the economically active population available from the 
International Labour Organization (ILO; Geneva, Switzerland). The distribution of the 
economically active population across nine industries or eight occupational groups was used 
to measure exposure to occupational asthmagens, particulate matter, noise, and ergonomic 
factors.
To calculate the burden of every continuous risk factor, the distribution of exposure needs to 
be estimated, which includes central tendency and dispersion parameters. We modelled 
mean and SD because these can be derived from nearly all published studies. In GBD 2010, 
for computational simplicity, all continuous risks were assumed to be normally distributed, 
so mean and SD were used to simulate the population distribution in the PAF calculation. 
Considerable evidence suggests that most risks are not normally distributed, so we have 
devoted substantial effort to choosing appropriate distribution for each risk factor.24–27 First, 
we modelled the natural log of the SD using observed data as a function of the mean and 
fixed effects on risk and super-region. Second, we evaluated the likelihood value of fitting 
normal, lognormal, gamma, beta, and inverse Gaussian distributions to the US National 
Health and Nutrition Examination Survey (NHANES) micro-data for systolic blood 
pressure, body-mass index (BMI), fasting plasma glucose, and cholesterol. We found that 
the lognormal distribution fit the available data best for all but three risk factors. For iron 
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deficiency and low bone mineral density, the normal distribution had the best fit. For high 
BMI, we used a beta distribution for which BMI is first transformed to be on a 0 to 1 scale, 
and the α and beta parameters for the distribution are fit to the mean and SD with the 
constraint that skewness cannot be negative.
Relative risks for systolic blood pressure have been corrected for regression dilution bias.28 
To be consistent with the adjusted relative risks for regression dilution bias, we have 
corrected exposure SDs for a measure of intertemporal variance in blood pressure observed 
in cohort studies; this effectively ensures that our values reflect usual systolic blood 
pressure.
Estimating the effects of risk factors on disease and injury outcomes
For 59 component risk factors, for which we estimate attributable burden using the relative 
risk and exposure formula, we estimated relative risks of mortality and morbidity based on 
either published meta-analyses, meta-analyses updated with new studies, or new meta-
regressions that include covariates such as age, sex, or country-level predictors for the GBD 
2013.
For every risk factor, relevant outcomes meeting the World Cancer Research Fund criteria 
of convincing or probable evidence for a causal association were identified. We used almost 
all outcomes from GBD 2010 and added 35 new outcomes (appendix p 10) to them through 
a comprehensive review of the list. For risk–outcome pairs for which evidence is only 
available on either mortality or morbidity, we assumed that the estimated relative risks 
applied equally to both. Where there was evidence of statistically different relative risks for 
mortality and morbidity, we used different relative risks for each. Of note, relative risks 
were not consistently higher or lower for mortality compared with morbidity. Appendix pp 
479–614 summarise the relative risks used by age and sex for each risk factor and outcome 
pair, and appendix pp 615–709 provide citations for all sources used for relative risks. We 
used relative risks from studies controlled for confounding but not controlling for factors 
along the causal pathway between exposure and outcome.
We used an updated meta-regression for water, sanitation, and handwashing with results 
from recently published studies.11,12 We conducted a new meta-regression for physical 
activity by converting the activity levels for which relative risk data are available to total 
MET mins of activity per week. DisMod-MR 2.0 was used to generate a continuous risk 
curve for every outcome as a function of MET mins activity per week. We updated the 
relative risks for childhood underweight, stunting, and wasting using a recently published 
study that did a pooled analysis of children enrolled in ten prospective cohorts in Africa, 
Asia, and South America.29,30 The updated relative risks for all three anthropometric 
indicators showed that they have no significant effect on malaria. Finally, we assumed that 
100% of the burden of protein-energy malnutrition was attributable to childhood 
underweight and wasting. The integrated exposure–response curve was used as a framework 
for ambient particulate matter pollution, household air pollution, secondhand smoke, and 
tobacco smoking in GBD 2010.31 For GBD 2013, we re-estimated these relations with 
recently published studies of relative risk and also extended their use to estimate the burden 
Page 7
Lancet. Author manuscript; available in PMC 2016 June 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
from secondhand smoke and household air pollution for chronic obstructive pulmonary 
disease.31–39
In some cases, evidence of the direct relation between a risk factor and a disease outcome 
was lacking or extremely sparse. For three risk factors (lead, sugar-sweetened beverages, 
and sodium), we estimated relative risks through a two-stage process.40–42 For sodium and 
disease outcomes other than gastric cancer, we first estimated the relation between 24-h 
sodium excretion and change in systolic blood pressure. Second, we estimated the relation 
between change in blood pressure and disease outcomes to estimate the effect of sodium on 
outcomes. This two-stage approach was also used for chronic lead exposure on adults (effect 
of bone lead through blood pressure) and sugar-sweetened beverages (through BMI).
Alcohol and high BMI are the only risk factors included in our current analysis that show a 
significant protective effect for selected outcomes, and the protective effects are restricted to 
certain groups (ie, premenopausal women for high BMI) or levels of intake (ie, 
alcohol).43,44 Recent studies confirmed previous meta-analyses that indicated a protective 
effect of high BMI on breast cancer in premenopausal women outside Asia–Pacific 
countries.45,46 These protective effects were estimated and included as negative attributable 
burden in our calculations.
Theoretical minimum risk exposure level (TMREL)
In the CRA framework, attributable burden is calculated with respect to a counterfactual risk 
exposure (see equation 2). In GBD 2010, we used the exposure distribution that minimises 
risk for the population, termed the theoretical minimum risk exposure distribution 
(TMRED).17 Based on a consultation with risk factor epidemiologists, we have chosen to 
simplify the TMRED and to choose a single level of risk exposure that minimises risk from 
all causes of DALYs combined, which we term the theoretical minimum risk exposure level 
(TMREL). The TMREL by its definition should minimise individual (and population level) 
risk and be theoretically possible to achieve, but not necessarily affordable or feasible to 
achieve. Table 1 shows the TMREL for each risk factor. In some cases, such as sodium 
consumption, the evidence supporting the selection of the TMREL is uncertain. In these 
cases, we include in the uncertainty estimation sampling a uniform distribution of different 
TMRELs.
As part of GBD 2013, we have modified the TMREL to be households with piped water 
connections and those who also boil or filter their water before drinking for unsafe water. 
Similarly, the TMREL for unsafe sanitation is now defined by the proportion of households 
that have access to sewer-connected toilet facilities.
In GBD 2010, a TMRED with a mean of 1 g per day of urinary sodium excretion was used 
for sodium intake. This value was supported by randomised clinical trials which showed that 
systolic blood pressure falls continuously as sodium is lowered to concentrations as low as 1 
g per day.47 The 2013 Institute of Medicine report, Sodium Intake in Populations: 
Assessment of Evidence, argued that the evidence of the benefit of lowering sodium below 
2·3 g per day was unclear.48 The PURE cohort study found a J-shaped association between 
urinary sodium excretion, mortality, and major cardiovascular events, with minimum risk of 
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death and major cardiovascular events observed between 3 g and 6 g of sodium excretion 
per day.49 Taking into account the potential overestimation of the Kawasaki formula used to 
estimate sodium excretion in PURE, the upper bound of minimum risk seems closer to 5 g 
per day. To account for the uncertainty surrounding the concentration of sodium that most 
minimises risk, we sampled a uniform distribution ranging from 1 g to 5 g per day to 
generate the TMREL. This choice, however, was controversial across the GBD 
investigators, with several diet collaborators proposing an uncertainty interval of 1–3 g per 
day. Following the GBD Study Protocol, the GBD Scientific Council made the final 
decision to use an uncertainty interval of 1–5 g per day.
For bone mineral density, we used the 99th percentile of age–sex subgroups of NHANES III 
studies between 2005 and 2010 data instead of 90th percentiles from NHANES III (used in 
GBD 2010). Use of the 99th percentile enables us to consider the bone density decrease by 
age, while capturing the excess risk of fracture caused by lower bone mineral density 
observed in elderly populations.
Attributable burden estimated using other approaches
For unsafe sex and occupational injuries for all outcomes, we did not use the relative risk 
and exposure method to estimate attributable burden. Because of absence of reliable relative 
risk estimates associating different occupations with injury outcomes, we used data for rates 
of fatal injuries reported by industry as related to occupation to calculate the PAF. This 
implicitly assumes that the TMREL would be zero for occupation-related fatal injuries. In 
view of the difficulty of fitting unsafe sex in the exposure–risk framework, we took a direct 
attribution approach and modelled the PAFs directly in DisMod-MR 2.0 for HIV. Direct 
attribution was also used for intimate partner violence and homicide, as well as drug use and 
hepatitis B and C.
Burden attributable to clusters of risk factors
There is interest in what fraction of the burden of disease is attributable to various 
combinations of risk factors or to all risk factors combined.50,51 To compute the joint risk 
factor burden for metabolic risks and combinations of metabolic risk factors with other 
behavioural or environmental risk factors requires assumptions about how one risk factor is 
mediated through other risk factors—for example, what fraction of the hazard associated 
with obesity is mediated through blood pressure or cholesterol? Recent studies have 
examined the fraction of high BMI mediated through elevated cholesterol and systolic blood 
pressure.52 Consistent with this approach for every two risk factors for an outcome, we 
estimated the fraction of risk that is mediated through the other risk based on published 
studies (appendix pp 710–11). Using this matrix of parameters carrying every two by two 
combination of the risk factors, we have computed the aggregated burden of disease for 
every level including behavioural, environmental and occupational, and metabolic risks, and 
finally for all risk factors using the following formula:
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Where J is a set of risk factors for aggregation, PAFjoasct is the population attributable 
fraction for risk factor i, MFjio is mediation factor for risk factor i mediated through j, cause 
o, age-group a and sex s, country c, and time t.
We estimated the joint burden of childhood wasting, stunting, and underweight. Published 
relative risks for wasting, stunting, and underweight, however, do not control for each other. 
We adjusted the published confounded relative risks for each indicator for the effect of the 
other two anthropometric indicators.29 Using the adjusted relative risks for all three 
anthropometric indicators, we have calculated the joint PAF for all three indicators assuming 
they were independent.
Role of the funding source
The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The authors had access to the data in the study and 
the final responsibility to submit the paper.
Results
The risk factors included in this analysis are estimated to account for a widely varying 
proportion of deaths and DALYs across causes at the global level. Figure 2 uses tree maps to 
represent the PAFs for all risks combined for each disease and injury for level 2 causes in 
the GBD hierarchical cause list for deaths and DALYs. Across the level 2 causes, the 
attributable fractions for deaths range from 0% for neonatal disorders to 88·7% (95% UI 
86·6–90·6) for cardiovascular and circulatory diseases. The next highest attributable 
fractions are 76·4% (95% UI 70·1–80·1) for diabetes, urogenital, blood, and endocrine 
disorders and 63·6% (61·2–66·1) for diarrhoea, lower respiratory infections, and other 
common infectious diseases. Table 2 shows that the attributable fraction for deaths due to all 
causes combined for all risk factors is 57·2% (95% UI 55·8–58·5) and the fraction for 
DALYs is 41·6% (40·1–43·0). The attributable fraction for YLDs due to non-communicable 
diseases for all risk factors combined (25·8% [24·0–27·6]) is much lower than for deaths or 
YLLs because some of the leading causes of YLDs such as mental and substance abuse 
disorders, musculoskeletal disorders, and other non-communicable diseases have low 
attributable fractions for the set of risks included in this study. For DALYs, in 2013 all risks 
explained a variable fraction ranging from 25·8% (95% UI 24·0–27·6) for injuries, to 43·8% 
(41·1–46·3) for non-communicable diseases, and 42·3% (40·6–44·1) for communicable, 
maternal, neonatal, and nutritional diseases. Within each broad disease and injury group, 
there is also substantial variation. Risks account for only 5·8% (95% UI 2·6–8·6) for 
maternal disorders and 0% for neonatal disorders, but 87·0 (84·6–89·3) for nutritional 
deficiencies. Within non-communicable diseases, all risks account for less than 6% of 
DALYs for digestive diseases, neurological disorders, and other non-communicable 
diseases.
To help quantify how each large group of risk factors interacts, figure 3 shows the fraction 
of burden for different outcomes that is explained by eight exclusive groupings: not 
explained by risks included in this study; behavioural risks alone; behavioural risks and 
environmental and occupational risks; behavioural risks and metabolic risks; environmental 
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and occupational risks alone; environmental and occupational and metabolic risks; 
metabolic risks alone; and the intersection of all three groups of risks (ie, behavioural, 
environmental and occupational, and metabolic). For all causes, all three primary clusters of 
risks have substantial overlap with the smallest proportional overlap being for environmental 
and occupational and metabolic risks. By contrast, cardiovascular diseases are dominated by 
metabolic risks and their considerable overlap with behavioural risks and environmental and 
occupational risks plays a much smaller role. Behavioural risks with a substantial overlap 
with environmental risks are the key explanations for neoplasms. For the category of 
diarrhoea, lower respiratory infections, and other common infections, there is no 
contribution from the metabolic risks included in this study but environmental and 
occupational and behavioural risks are nearly equal with substantial overlap. Figure 4 shows 
the same breakdown of the overlap of the three clusters of risk factors by age. Because we 
have included no risk factors for major neonatal causes in this analysis, the fraction 
explained by the three clusters rises rapidly with age in children. The fraction explained 
declines again to a low at 10–14 years. In young adults, behavioural risks are the dominant 
risks with an increasing component related to metabolic risks at older ages. Environmental 
risks explain a relatively constant share of burden in all age groups.
The leading risk factors globally have changed substantially from 2000 to 2013 (figure 5; 
see appendix pp 712–20 for 1990 and for results for males and females separately). In 2000, 
the leading cause of attributable DALYs (level 2 in the risk hierarchy) was child and 
maternal malnutrition for both males and females, accounting for more than one in ten 
DALYs. Other risks that are characteristic of poor communities including unsafe water, 
unsafe sanitation and handwashing, and air pollution caused nearly 5% each of DALYs for 
males and females. By 2013, child and maternal malnutrition had dropped from 10·4% in 
males and 12·5% in females in 2000 to 6·55% and 8·02%, respectively. Risks for males at 
the global level in 2013 accounting for more than 5% of DALYs were the aggregation of 
dietary risks, high systolic blood pressure, tobacco smoke, alcohol and drug use, child and 
maternal malnutrition, air pollution, high fasting plasma glucose, and high BMI. In females, 
the risks in 2013 accounting for more than 5% of DALYs were dietary risks, child and 
maternal malnutrition, high systolic blood pressure, high BMI, and air pollution. Other risks 
that account for more than 2% of global DALYs in men and women include high fasting 
plasma glucose, unsafe water, unsafe sanitation, lack of handwashing, unsafe sex, and high 
cholesterol. The most notable differences in the magnitude of risk factors between males and 
females are the more prominent role for females of child and maternal malnutrition, high 
BMI, and sexual abuse and violence; whereas in males, tobacco, alcohol, and drug use are 
much more prominent than in females.
The global pattern masks tremendous regional variation in the profile of risks, particularly in 
sub-Saharan Africa compared with the rest of the developing and developed world. Figure 6 
shows the leading risk factors in terms of attributable DALYs for sub-Saharan Africa in 
2013 for both sexes combined: child and maternal malnutrition, unsafe sex, and unsafe 
water, sanitation, and handwashing practices. In females, the next most important is air 
pollution (in this case mostly household air pollution) and high systolic blood pressure. In 
males, alcohol and drug use is also an important risk factor.
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The period 2000–13 was characterised by a major shift in the size and relative magnitude of 
many risk factors (figure 7). Childhood undernutrition went from the number one global risk 
factor in terms of attributable DALYS to the fourth in 2013, a drop of 45% (39–51) in the 
number of DALYs. Unsafe water declined 37% (30–44) dropping from fourth to eighth; 
likewise unsafe sanitation dropped from ninth to 16th. Suboptimal breastfeeding declined 
40% (32–47) from rank 11 to rank 19. Unsafe sex went from 10th to 9th from 2000 to 2013; 
it should be noted that the peak attributable burden associated with unsafe sex was in 2005. 
Several risks related to non-communicable diseases have risen in prominence. High systolic 
blood pressure increased from second to first. Smoking increased from third to second. High 
BMI increased from fifth to third and high fasting plasma glucose also increased from eighth 
to fifth. Ambient particulate matter pollution increased 6% (1–12) leading to a rank increase 
from 13th to 12th. Several diet components—most notably low fruit, high sodium, and low 
whole grains—increased in rank and absolute attributable burden over the period. We can 
isolate the impact of changes in population size and age composition by examining the 
change in the number of attributable DALYs compared with the change in the age-
standardised rate of attributable DALYs. In fact, only five risk factors had increases in the 
age-standardised attributable DALY rate: unsafe sex, diet high in red meat, diet high in 
sugar-sweetened beverages, occupational carcinogens, and drug use. In terms of the number 
of attributable DALYs, seven risks declined: vitamin A deficiency, childhood 
undernutrition, unsafe sanitation, secondhand smoke, no handwashing with soap, unsafe 
water, and suboptimal breastfeeding. Among the components of unsafe water, sanitation, 
and handwashing, the most important is unsafe water followed by unsafe sanitation and then 
no handwashing with soap.
Deaths and DALYs for all ages and both sexes combined for the full risk factor hierarchy 
are provided in table 3. Appendix pp 52–87 provides a further breakdown for each risk–
outcome pair. All risk factors combined accounted for 25·1 million deaths in 1990, 
increasing by more than one-fifth to 30·8 million deaths in 2013. Although the number of 
deaths attributed to all risks increased substantially, the global all-risk all-cause PAF 
increased only 3·4 percentage points from 52·8% to 56·2%. The trends in DALYs attributed 
to all risk factors are quite different than those for deaths: total DALYs did not change from 
1990 to 2013 and the PAF decreased by 0·05 of a percentage point. For most risks that affect 
non-communicable diseases, the number of deaths or DALYs that are attributable to those 
risks increased; however, the age-standardised PAF increased by more than 10% for a subset 
of risks, including most occupational carcinogens, occupational noise, occupational 
ergonomic factors, alcohol use, drug use, diet low in whole grains, diet low in milk, diet 
high in red meat, diet high in processed meat, diet high in sugar-sweetened beverages, diet 
with suboptimal calcium, intimate partner violence, unsafe sex, low physical activity, high 
fasting plasma glucose, high systolic blood pressure, high BMI, and low glomerular 
filtration rate.
In most cases, the trend in the number of deaths attributed to a risk factor is similar to the 
trend in the number of DALYs attributable to the same risk from 1990 to 2013. Differences 
in the rates reflect the age pattern of the attributable events for a risk. An unusual case is air 
pollution, for which the number of attributable deaths increased but attributable DALYs 
declined. This finding is due to the trends for ambient particulate matter pollution, for which 
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deaths increased from 2·2 million to 2·9 million deaths, and household air pollution from 
solid fuels for which deaths remained constant at 2·9 million. Because deaths due to 
household air pollution on average occur at much younger ages, the trend in this risk drives 
the overall trend in the joint risk of air pollution.
The combined effect of air pollution was 5·5 million deaths in 2013 and 141·5 million 
DALYs. There were roughly equal contributions from household air pollution (2·9 million 
deaths and 81·1 million DALYs in 2013) and ambient particulate matter pollution (2·9 
million deaths and 69·7 million DALYs in 2013). Lead exposure accounted for an increased 
number of deaths in 2013 as compared with 1990 (853 000 compared with 668 000). Taken 
together, occupational carcinogens caused 304 000 deaths globally in 2013 and 5·8 million 
DALYs; asbestos exposure accounted for nearly two-thirds of the burden of all occupational 
carcinogens. In total, occupational risks accounted for 55·4 million DALYs, of which 
occupational ergonomic factors accounted for 38·1%. As a cluster, childhood undernutrition 
accounted for 1·3 million child deaths in 2013 and 120 million DALYs. Iron deficiency, 
vitamin A deficiency, and zinc deficiency each accounted for less than 200 000 deaths; 
however, iron deficiency is a major cause of DALYs due to its crucial role as a cause of 
anaemia.
The number of deaths attributable to tobacco smoking continued to increase from 4·6 
million in 1990 to 5·8 million in 2013, and from 115·9 million DALYs to 134·2 million 
DALYs over the same period. Secondhand smoke accounted for an additional 331 000 
deaths and 9·3 million DALYs. Alcohol use accounted for 2·8 million deaths and 99·3 
million DALYs in 2013, with both deaths and DALYs increasing over time. Among the 
components of diet, the most important in terms of deaths and DALYs in 2013 were diets 
high in sodium and low in fruit, followed by low whole grains and low vegetables. Among 
the metabolic risks, high systolic blood pressure is more than twice as important as the next 
most important factor—high BMI, followed by high fasting plasma glucose.
One simple way to examine the complex results by country is to examine the leading risk 
factor in terms of DALYs with risk factors broken down to level 3 in the risk factor 
hierarchy (figure 8). For men (figure 8A), a large set of countries from North Africa and the 
Middle East through to south Asia and east Asia and into Eastern Europe have high systolic 
blood pressure as their leading risk. Another broad set of countries in west, east, and central 
sub-Saharan Africa have childhood undernutrition as the leading risk. Unsafe sex is the 
leading risk in a set of countries in east and southern Africa with large HIV epidemics. 
Tobacco is the leading risk in most high-income countries and alcohol use is the leading risk 
in many countries in Latin America. For women (figure 8B), the pattern is notably different. 
High BMI is the leading risk for most countries in North and South America with only three 
exceptions (Canada, Guatemala, and Uruguay). High BMI is also the leading risk in Spain, 
France, Switzerland, Belgium, most of North Africa and the Middle East, Australia, and 
New Zealand. High systolic blood pressure is the leading risk in most of Central and Eastern 
Europe, central Asia, south Asia, and east Asia. Cambodia stands out as having household 
air pollution as the top risk factor for women. In sub-Saharan Africa, the leading risks are 
undernutrition and unsafe sex for both men and women in sub-Saharan Africa.
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Figure 9 provides the ten leading risk factors in terms of attributable DALYs (level 3 in the 
risk hierarchy) for each country in 2013 for both sexes combined. The top 15 global risks 
have been coloured to highlight where country and regional patterns diverge from global 
patterns. In high-income regions, most countries had high BMI, high systolic blood pressure, 
and smoking as the top three risks. Brunei, Singapore, and Japan had high fasting plasma 
glucose in the top three. Alcohol use was the second leading risk in South Korea. Low 
glomerular filtration rate was an important risk in several countries such as Italy. In Central 
Europe, Eastern Europe, and central Asia, the leading risk factor for both sexes combined 
was high systolic blood pressure, followed by smoking or high BMI. In Mongolia, Belarus, 
and Russia, alcohol was the second leading risk factor. Childhood undernutrition remained a 
top five risk in Tajikistan, Turkmenistan, and Uzbekistan. In Latin America and the 
Caribbean, high systolic blood pressure or high BMI were the leading risks in most 
countries. Notable exceptions are in Haiti and Guatemala, where childhood undernutrition 
was the leading risk. Haiti also stands out with unsafe sex as the second leading risk factor. 
In this region, either high fasting plasma glucose or alcohol use were top five risks in nearly 
every country. Unsafe water was a top five risk in Haiti and Guatemala. In east Asia, the 
leading risks were high systolic blood pressure, tobacco smoking, and high sodium intake. 
In Oceania, high BMI and high fasting plasma glucose were the leading risks in all 
countries, except in Papua New Guinea where smoking and childhood undernutrition were 
most important and Vanuatu where high systolic blood pressure was the top risk, followed 
by high BMI. In southeast Asia, high systolic blood pressure and smoking were dominant 
risks, except in Laos and Timor-Leste where childhood undernutrition was the leading risk. 
Household air pollution was a top five risk in many countries in the region. In south Asia, 
high systolic blood pressure was the leading risk, except for in Afghanistan and Pakistan. In 
India, high fasting plasma glucose was the second leading risk followed by household air 
pollution, unsafe water, and childhood undernutrition. In North Africa and the Middle East, 
high BMI was the leading risk in nearly all countries, and most countries had high fasting 
plasma glucose and high systolic blood pressure as top three risks. Sudan and Yemen stand 
out with childhood undernutrition and unsafe water as top three risks. In sub-Saharan Africa, 
there are four patterns: countries where the leading risks were childhood undernutrition, 
unsafe water, and unsafe sanitation; countries where the leading risks were unsafe sex, 
childhood undernutrition, and unsafe water; countries in southern Africa with unsafe sex and 
alcohol use as leading risks, and island nations such as the Seychelles and Cape Verde with 
high systolic blood pressure as leading risk. South Africa is notable for the top three risks 
being unsafe sex, high BMI, and alcohol use.
Discussion
Our analysis of 79 risks divided into three broad groups of behavioural, environmental and 
occupational, and metabolic risk factors shows that together they explain slightly greater 
than 57% of global deaths and more than 41% of global DALYs. Each of the risk factors 
included in this analysis is modifiable, pointing to the huge potential of prevention to 
improve human health. Globally, behavioural risk factors are the most important followed 
by metabolic and environmental and occupational risk factors. This pattern varies 
substantially: in many countries in sub-Saharan Africa, environmental risk factors, mainly 
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water, sanitation, no handwashing, and household air pollution, are more important than 
metabolic risks. By 2013, the six most important risk factors globally were dietary risks, 
high systolic blood pressure, child and maternal malnutrition, tobacco, air pollution, and 
high BMI.
Since 1990, there has been a profound change in risk factors associated with the global 
epidemiological transition. In 1990, child and maternal malnutrition and unsafe water, 
sanitation, and handwashing were the leading risks for global DALYs, but now these have 
been replaced by dietary risks and high systolic blood pressure. A large group of risk factors 
recorded declines of more than 10% in age-standardised PAFs from 1990 to 2013, including 
unsafe water, sanitation, and handwashing; household air pollution; suboptimal 
breastfeeding; childhood undernutrition; vitamin A deficiency; secondhand smoke; and diet 
high in trans fats. By contrast, for several risk factors, age-standardised PAFs are increasing: 
intimate partner violence, drug use, high BMI, high fasting plasma glucose, low glomerular 
filtration rate, unsafe sex, and several components of diet (ie, low whole grains, high red 
meat, and high sugar-sweetened beverages). This transition in risks reflects a general shift 
from environmental risks towards behavioural and metabolic risks. These insights should 
strengthen our understanding of the epidemiological transition and our capacity to forecast 
population health.
The risk factors included in this study are those that met our inclusion criteria. After 
removing the effect of these risks, a substantial fraction of global deaths and DALYs 
remain. What might account for the unexplained component of death rates and the even 
greater unexplained component for YLDs? Risk-deleted death rates (not shown in this 
paper) vary substantially across countries. Other environmental risks, such as soil and water 
contamination, or behavioural risks, such as lack of sleep, could explain a component of the 
unexplained variation.53–55 Inclusion of new risk factors in future iterations of the GBD 
might reduce the unattributed fraction. Social, economic, and cultural factors could be an 
important part of the explanation, but only the components of these risks expressed through 
differential behaviours or environmental risks have been incorporated in the GBD CRA 
work so far. Higher risk-deleted age-specific death and DALY rates are seen in low-income 
countries and those countries with lower educational attainment. Parts of both effects would 
be mediated through access to care and coverage with curative interventions. From a quarter 
to half of the decline in cardiovascular and circulatory diseases in high-income countries 
have been attributed to treatments.56–58 Another aspect of understanding the unexplained 
morbidity is that epidemiological studies have studied fewer of, and yielded fewer insights 
into, the drivers of key contributors to YLDs, such as mental and substance use disorders, 
musculoskeletal disorders, and neurological disorders. More research on the areas we know 
less about might redress this imbalance.
The behavioural risk factors included in this study range from explaining fewer than 19% of 
DALYs in 2013 in the Maldives to more than 54% in South Africa. There is substantial 
scope through changing behaviours to improve individual and population health. Although 
there is a role for drugs and vaccines to mitigate the harmful effects of some behaviours, 
interventions to affect and change behaviours must be the primary mechanisms to reduce 
this burden. In view of their large role, funding for research on interventions to change 
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health behaviours by major research funders has been scarce. Intellectual property rights are 
harder to establish for behavioural change interventions so there are fewer incentives for the 
private sector to pursue this type of investigation. One exception to the absence of private 
sector engagement in this arena is the recent rise of personal health mobile device 
applications. More behavioural and social science research into solutions for behavioural 
risks, particularly those that are increasing such as the nexus of diet, physical activity, and 
BMI, is urgently needed.
Shifting from the behavioural, environmental and occupational, and metabolic risk factors to 
a more comprehensive view of risks including genes, the microbiome, public health, and 
medical care interventions, and distal social, economic, and cultural factors, would provide a 
more coherent account of health and its causes. The GBD has sought to provide a 
standardised framework, an evidence-based accounting, of the contribution of diseases and 
injuries and selected risks to deaths, YLLs, YLDs, and DALYs. It is natural to extend this 
framework progressively to quantify the broader set of risks for health outcomes. The rules 
of evidence, however, used so far in the CRA studies might need to be modified to allow 
this expansion. Social, economic, and cultural factors, for example, are mediated through 
several interactive pathways in the causal web; we would not expect that effect sizes would 
be consistent across contexts. This expansion will not be a quick undertaking, but the annual 
revisions of the GBD will provide an opportunity to encompass this broadened vision 
progressively.
The aggregation of the 14 specific components of diet accounted for nearly one tenth of 
global DALYs in 2013. At the global level, the most important contributors to the overall 
burden of diet are low fruit, high sodium, low whole grains, low vegetables, and low nuts 
and seeds. But diet patterns vary greatly across countries and as a result the most important 
diet components vary substantially by country. Our diet estimates do not reflect the total 
effect of diet on health. Dietary risk factor exposures reflecting the literature on diet 
epidemiology are standardised to a 2000 calorie diet, resulting in dietary exposures that 
reflect diet composition rather than direct caloric contribution for each risk factor. This 
holds true for all dietary risks except for sugar-sweetened beverages, for which the effect of 
calories is captured through effects on BMI. Other dietary components probably affect 
overweight and obesity, in both protective and detrimental directions.59,60 If one were to 
quantify the contribution of diet mediated through weight gain and BMI, the overall effect of 
diet would be much larger than is estimated here. Since GBD 2010, the PREDIMED 
randomised clinical trial reported an effect of nut consumption that was quite consistent with 
the estimated effect from cohort studies.61,62 Yet criticism of dietary studies and the effects 
derived from them abounds.63,64 A considerable challenge in the diet estimation is that 
component exposures are also likely to be interrelated within individuals. There are 
correlations across individuals in the intake of different diet components, and there might 
also be synergistic or antagonistic effects of dietary components that are consumed together. 
Furthermore, various methods for diet recall all have substantial measurement error and 
biomarkers to measure recent diet have not been operationalised to date. In view of the 
importance of diet in this analysis, more attention should be paid to quantifying the 
correlation structure of diet components and the effects of different diet components on 
weight gain, including the effect of total caloric intake. Although there are many 
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opportunities to improve the estimation of the burden attributable to diet, the potential 
magnitude of the benefits of shifting to a more optimum diet justify concerted examination 
of policy options to shift individual and national diets now.
After diet, high systolic blood pressure is the next most important global risk factor 
accounting for 9·6% of all DALYs, up from 5·6% in 1990, making high systolic blood 
pressure larger than ischaemic heart disease and three times larger than HIV/AIDS in terms 
of DALYs. Our estimates for DALYs attributable to high systolic blood pressure in 2010 are 
15% higher than in the GBD 2010 analysis for two primary reasons: new estimates of the 
mean blood pressure for each country, age, and sex reflecting new data and an improved 
model; and the shift to use of the lognormal distributional assumption, which more closely 
follows the available data. Despite its importance, there has been comparatively little global 
health policy discussion or initiatives focused on blood pressure. The WHO voluntary 
targets for non-communicable diseases have called for a 25% reduction in the prevalence of 
high blood pressure by 2025. For World Health Day 2013, WHO issued a global brief 
calling for salt reduction and integrated primary care management as cost-effective routes to 
address the burden of high blood pressure. Although these efforts are welcome, high blood 
pressure needs a stronger and more coherent global response; one that will both monitor the 
burden of high blood pressure and provide policy guidance for the most effective 
intervention strategies tailored to different contexts.
One key component of diet related to systolic blood pressure is high sodium intake; we find 
that 3·0% of global DALYs can be related to sodium intake (95% UI 1·8–5·3). The wide UI 
reflects the uncertainty in the sodium TMREL from 1 g to 5 g per day. This widening of the 
TMREL compared with that in GBD 2010 of 1 g per day reflected the growing debate on the 
optimum level of sodium intake. On the one hand, the PURE cohort study found a J-shaped 
association between sodium, mortality, and major cardiovascular events among 101 945 
individuals in 17 countries. On the other hand, the J-shaped curve could be due to residual 
confounding or reverse causation. The findings from PURE have generated much debate on 
the methods used to measure sodium intake, as well as the potential for low sodium intake to 
reduce blood pressure but raise mortality through some aspect of the renin–aldosterone 
system.49,65,66 While the debate on optimum sodium intake is likely to continue, even with a 
much wider TMREL, high sodium intake is a major global risk. If the optimum sodium 
intake is 5 g, we still estimate that sodium accounts for at least 1·6% of global DALYs, 
which is more than the global DALYs caused by tuberculosis. Voluntary and mandatory 
reductions in sodium content of processed foods have been tried and found to be cost 
effective in some settings.67,68 Salt substitutes such as potassium chloride or blends of 
sodium and potassium chloride are being tested in randomised trials.69,70 Even as the 
science on how far individuals should reduce their sodium consumption will continue to 
evolve, the argument for a population-level strategy to reduce sodium intake is compelling.
Maternal and child undernutrition was the leading global risk in this analysis in 1990 and 
remains the third most important in 2013, causing 6·8% (95% UI 6·2–7·4) of global DALYs. 
This cluster of risks includes in terms of importance childhood undernutrition, iron 
deficiency, suboptimal breastfeeding, vitamin A deficiency, and zinc deficiency. Compared 
with the GBD 2010 analysis, this cluster of risks is estimated to account for more DALYs 
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primarily because for childhood undernutrition we have computed the joint distribution of 
child stunting, wasting, and underweight. In the GBD 2010, only child underweight was 
computed. By examining the combined effects of all three anthropometric measures, we 
have increased the estimated burden by 71%. In sub-Saharan Africa, childhood 
undernutrition remains the leading risk factor emphasising the strong link of this risk to 
socioeconomic development; by contrast, in developing countries outside sub-Saharan 
Africa, childhood undernutrition has declined profoundly. By estimating the combined 
effects of stunting, wasting, and underweight, we have documented the enormous burden 
still caused by these risks in the poorest countries. The joint estimation, however, is based 
on back-calculating the relative risks for stunting, wasting, and underweight from published 
risks that are confounded by each other. These estimations will be strengthened by pooled 
analysis of available cohort data that directly computes the independent relative risks and 
their joint distribution.
Particulate matter pollution from both ambient sources and from household use of solid fuels 
is a major risk. Our estimates for DALYs attributable to ambient particulate matter air 
pollution are slightly lower than those in GBD 2010, but our estimates for household air 
pollution are lower by 22% for 2010. The reduction reflects the much larger number of 
studies used to map household fuel use to PM2·5 exposure levels in different settings. 
Regardless of the exact values of these estimates, both ambient particulate matter pollution 
and household air pollution are estimated to be major risk factors, particularly for non-
communicable diseases. These environmental risks are classic examples for which public 
policy is required to mitigate risk.71 Because of the concave relation between PM2·5 
concentration and relative risk, the benefits of reducing exposure per unit of exposure to 
PM2·5 are greater at lower levels of exposure than at higher levels. This benefit puts a 
premium on reducing exposure down to low levels near the TMREL. Both for ambient and 
household air pollution, the full implications of the concave nature of the risk curve need to 
be factored into policy interventions.
Tobacco use remains a major determinant of global health, ranking second in terms of risk 
in 2013, although the age-standardised DALY rate has fallen by 32% since 1990. Although 
the prevalence of smoking seems to be declining or stable in most countries, the burden of 
tobacco suggests that it ought to remain a key focus of global health policy debates.20 
Continued vigilance is absolutely required to ensure that women in developing countries, 
particularly in those with rapidly growing economies, do not begin to smoke in large 
numbers as women have done in some high-income countries. Equally, the failure of 
societies to bring down tobacco use among men faster than what has been observed over the 
past three to four decades, when the magnitude of the hazards had been well established, is 
of great public health concern. The experience of countries such as Australia, the UK, and 
USA, where male smoking prevalence has fallen from 70% post war to 15–20% today, 
provides clear evidence that targeted tobacco control strategies can work, but are likely to 
require a combination of strong government commitment, fiscal measures, and an informed 
and active civil society and non-governmental organisation sector to advocate effectively for 
comprehensive tobacco control measures.33,72 Without all of these ingredients, now 
facilitated by WHO’s stewardship and private philanthropy driving the MPOWER 
programme, progress will be slow, difficult, and at risk of reversals.73,74
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Alcohol remains a major risk, ranking sixth among level 3 global risk factors, whereas all 
illicit drug use combined ranks 22nd. Yet, although drugs are internationally controlled by 
treaties and a UN agency, there is no international public health treaty on alcohol. The WHO 
voluntary targets for non-communicable diseases have called for a 10% reduction in the 
volume of alcohol consumption by 2025 where this is nationally appropriate, but this is a 
substantially more modest target than those for other leading NCD risk factors, and policy 
initiatives for alcohol are recommended only in general terms.75 There is a need for a more 
coherent and effective global response, including detailed policy guidelines based on the 
substantial evidence available on effective intervention strategies.
Our estimates for the burden attributable to high BMI are substantially higher than those in 
GBD 2010 for two reasons. First, based on new published pooled cohort or meta-analyses, 
we added several new outcomes related to high BMI. Second, we have more accurately 
captured the fraction of the population with high BMI using the beta distribution compared 
with the assumption of a normal distribution. There remains some debate in the literature on 
the risks associated with overweight. Flegal and colleagues76 reported in a meta-analysis of 
studies reporting on broad categories of BMI that risk is lowest in the category of 
overweight.21 Pooled cohort analysis with more detailed BMI categories with a much larger 
number of person-years of exposure found a regular association with rising BMI from 23 
onwards.77 Part of the discrepancy in the findings is also related to how many years of 
observation are excluded from the analysis to remove the bias of sick individuals having 
lowered BMIs. Stokes and colleagues showed that re-analysing NHANES follow-up data by 
maximum lifetime BMI suggested that people in the overweight category were at 
substantially elevated risk (relative risk 1·28) compared with normal weight 
individuals.78–81 We believe that the balance of the evidence clearly supports our TMREL 
of 21–23 and that the pooled cohort studies provide the most robust relative risks available 
to date for this analysis. Regardless of this debate, however, the burden attributable to high 
BMI more generally is large and increasing at the global level. Intensified research and 
policy experimentation into the options to reduce BMI or to slow its increase is needed.
Our estimates of the burden attributable to unsafe water, unsafe sanitation, and no 
handwashing with soap are substantial: 38 countries have more than 5% of DALYs 
attributable to these risks, rising as high as 16% in Chad. Redefining the risk to be unsafe 
water and unsafe sanitation, and adding in the risk from lack of handwashing with soap, 
increases the burden attributable to the cluster of water, sanitation, and hygiene. It also has 
important policy implications: in terms of risk reduction, achieving the MDG targets of 
improved water and sanitation would have little effect on reducing diarrhoea morbidity and 
mortality. Based on new meta-regressions, much of the potential benefit of water and 
sanitation is through achieving levels of access that are far higher than those in the MDG 
category of improved water or sanitation.12 These findings are reflected in the much larger 
attributable fractions for unsafe water and unsafe sanitation as compared with improved 
water and improved sanitation. We believe that future monitoring efforts related to water, 
sanitation, and hygiene, such as those that might emerge from the sustainable development 
goals, should take into account the levels of risk associated with different levels of access. 
Setting the goal to be minimum risk, the approach taken here, would also mean that many 
countries, including some middle-income countries, have a great distance to go. The finding 
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that no handwashing with soap is a global risk present in all regions is a reminder that this 
nexus of risks is relevant to all countries, not just the poorest.
An important aspect of the GBD 2013 has been the attempt to estimate the joint 
counterfactual for metabolic risks and all risks together, taking into account mediation of 
some risks through others such as BMI through systolic blood pressure. We assume that the 
fraction mediated through another risk is the same across countries based on the available 
literature.52 A more precise approach would be to estimate the correlation of the risks 
directly in each population and, through pooled studies, analyse the relative risks for the full 
joint distribution of each combination of risks—eg, BMI and blood pressure. Administrative 
data such as electronic medical record data might provide a useful database to understand 
the correlation of risks in different populations. Use of the average level of mediation noted 
in studies probably means that, at the global level, our results are not biased up or down, but 
in specific countries our results could be either too high or too low for the joint distribution 
of risks. We propagated the uncertainty in the fraction mediated into the final results, but 
this might still underestimate uncertainty because we only incorporated the uncertainty in 
the mean estimate of mediation. However, because the joint PAF for cardiovascular disease 
across all risks is so large—ranging from 63·5% in Chad to 94·3% in Belarus in 2013—these 
limitations of the mediation analysis would have only a minimum effect on the 
cardiovascular disease PAF due to all risk factors. Mediation for other major outcomes plays 
a much smaller part than it does for cardiovascular diseases.
In GBD 2010, the integrated exposure–response curve for PM2·5 was introduced to take a 
more unified view of risk exposure across different sources of PM2·5.31,82 The crucial 
assumption is that the PM2·5 is a robust indicator of the risk associated with a mixture of 
pollutants from ambient air pollution, tobacco smoking, secondhand smoke exposure, and 
household air pollution exposure to PM2·5. This simplifying assumption has received 
substantial attention.83,84 In GBD 2013, we have more consistently mapped the outcomes 
across this set of sources of PM2·5: pneumonia has been added as an outcome of tobacco 
smoking, which has been supported by tobacco cohort studies.85,86 We have expanded 
PM2·5 to cover child and adult lower respiratory infections. In view of the crucial 
importance of the integrated exposure–response curve to the validity of estimates for 
household air pollution particularly, further research on this is required. For household air 
pollution, one of the crucial steps in the analysis is to map from the proxy measure of 
exposure to the level of PM2·5 that is actually experienced, to estimate the relative risk from 
the integrated exposure–response curve. In GBD 2010, this was mapped using a large study 
from India and no uncertainty in this mapping was incorporated into the final results. For 
GBD 2013, we have based this on 67 studies from eight regions and have propagated 
uncertainty in this mapping into the final results. The net effect of these changes has been to 
widen uncertainty and capture regional variation in the level of PM2·5 exposure in 
households using solid fuels.
A major improvement for CRA implemented in the GBD 2013 has been the use of exposure 
distributions across individuals that are more consistent with the available survey data. The 
shift from assuming normal distributions to lognormal distributions has important effects on 
metabolic risks, as does the use of the beta distribution for BMI. Fasting plasma glucose has 
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an unusual distribution that is not well represented by any of the parametric distributions 
that we tested. In future research, it will be important to explore the use of alternative 
methods such as mixture distributions or non-parametric approaches. More attention to the 
consistency of the distribution of exposure across populations conditional on mean and SD 
is warranted in future cycles of the GBD.
At the global level, the correlation of the number of DALYs attributable to the same risks 
for the year 2010 across GBD 2010 and GBD 2013 is 0·97. There are several notable 
changes detailed above for risks such as high BMI, high systolic blood pressure, and unsafe 
water, sanitation, and handwashing. For other risks there are also changes, but, globally, 
they are generally smaller than 10% in the year 2010. At the country level, however, there 
are more important changes. The correlation coefficient for PAFs at the country level is 
0·84. These changes can be traced to changes in exposure where newer data or model 
revisions have altered the assessments.
The attributable burden of disease formula (equation 1) multiplies PAFs by deaths, YLLs, 
YLDs, or DALYs. All the limitations of the estimates of deaths, YLLs, YLDs, and DALYs 
apply to this analysis.18,19 There are, however, several important limitations that relate to the 
components of the PAF analysis. First, for most outcomes, cohort or randomised controlled 
trial data are available for either mortality or morbidity, but rarely both. Second, we apply 
relative risks from meta-analyses or meta-regressions for a disease category such as 
ischaemic heart disease to all the sequelae of that disease, but more detailed studies might 
reveal different relative risks. Third, the data representativeness index for some risk factors 
is quite low—eg, handwashing and diet low in polyunsaturated fatty acids. Our modelling 
strategies attempt to quantify uncertainty as captured in the available data, but it remains 
possible that new data collected in countries without data might reveal levels of exposure 
that are outside the uncertainty intervals that we have estimated. Fourth, for unsafe water 
and unsafe sanitation, we assess the availability of infrastructure not the use of the 
infrastructure. Our estimates are not biased because the relative risks are derived from 
similar exposure definitions. Fifth, some risk factors are measured with very coarse proxies 
for exposure. The most extreme example is zinc deficiency, for which we analysed Food and 
Agriculture Organization of the United Nations food balance sheets for absorbable zinc and 
estimated the balance between theoretical intake and physiological requirements. Although 
the proportion of people with estimated inadequate zinc intake is a proxy of zinc deficiency, 
it lacks the anchor to individual level measurement of the exposure as a gold standard to 
estimate the number of people at risk. Other examples of the use of exposure proxy 
measurements are the proportion of the population in coarse occupational categories as a 
proxy for exposure to specific carcinogens, and the type of fuel used as a proxy for 
household air pollution. Capturing geographical variation and uncertainty in the mapping 
from household solid fuel use to PM2·5 exposure enhances the validity of our findings and 
uncertainty intervals. Nevertheless, more direct PM2·5 measurement in households to 
calibrate the more widely available data for fuel use would be strongly preferable. Sixth, 
robust models to estimate variation in the SD of risk exposure are harder to develop than are 
estimations of the mean. In many cases, we are only able to capture regional variation in the 
SD. Measured SDs from studies are an overestimate of the true SDs, because they include 
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the effects of measurement error. We have not in this study corrected SDs for measurement 
error except for correcting observed systolic blood pressure to usual blood pressure.
Seventh, we have not systematically corrected relative risks for publication bias. In some 
cases, there are not enough studies to do this. Eighth, relative risks have not been corrected 
for non-masking in studies. For example, if the meta-regression of handwashing studies is 
corrected for non-masking, the effect size would be non-significant. Many risks, however, 
cannot be studied in a masked fashion, such as tobacco smoking. Correction of some risks 
but not others could introduce worse issues of comparability so we have chosen for this 
study to not correct for non-masking in study design.
Ninth, with few exceptions, we assume that relative risks are universal across countries for a 
given age–sex group with few exceptions.45,46 Some studies have argued that the BMI 
relative risk curve and TMREL might vary geographically, but there was insufficient 
evidence to date to identify statistically significant differences in relative risks, except in the 
case of breast cancer. Generally, as further evidence accumulates, we might find more 
examples of non-universal relative risks. We have not incorporated into our uncertainty 
intervals any qualitative assessment of the potential for non-universal risks.
Tenth, some heterogeneity remains around the implementation of the TMREL concept. For 
example, for exposure to ambient particulate matter pollution, the TMREL has been chosen 
as between 5·9 μg/m3 and 8·7 μg/m3, but zero PM2·5 arguably might be the lowest risk. 
Cohort data to support the notion that the relative risk continues to decline below 5·8 μg/m3, 
however, are limited. Eleventh, for unsafe sex, HIV risk from injecting drug use, and 
occupational injuries, we have not used the relative risk and exposure PAF calculation. 
Attributable fractions of HIV for unsafe sex and injecting drug use have been based on 
direct evidence of the attributable fraction. These direct or categorical approaches might not 
yield results that are strictly comparable to the risks estimated with the relative risk and 
exposure model.
Twelfth, for risk factors for which we do not correct for mediation, we assume their joint 
effect can be estimated with the multiplicative risk model. This model, while plausible, 
might not accurately capture how all risks interact. Unfortunately, there are no cohort studies 
available of sufficient size to study the nature of these interactions in more detail. 
Thirteenth, the fraction of a risk factor mediated through another risk factor might be 
underestimated because of measurement error in both risk factors (similar to the case of 
regression dilution bias due to the exposure measurement error).28
Fourteenth, for air pollution, there are few studies that allow estimation of the quantitative 
contribution of household air pollution to ambient air pollution or vice versa.87 As such we 
might have underestimated the burden of household air pollution as a single risk factor; we 
might also have overestimated the burden of air pollution combined. Lastly, estimating 
burden for risks divided into polytomous risks might underestimate their burden compared 
with estimating burden with a continuous risk variable.
Strategies and policies to improve the health of populations should be guided by the 
comparative importance of health loss arising from exposure to major risk factors, whatever 
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their position in the causal chain. It is the underlying causes of diseases and injuries that 
ought to guide prevention efforts, and knowing their comparative magnitude and trends in 
causing health loss is arguably among the most important information required by countries 
to prioritise health programmes and policies. The comprehensive assessment of risk factors 
presented in this study provides a clear indication of where prevention programmes aimed at 
risk factor modification can have major effects on health. The challenge for governments 
and the health development community more broadly is to heed this knowledge about the 
comparative effect of health risks more assiduously, and orient health policies towards their 
mitigation with much greater conviction than that currently observed. Yet our findings that 
the list of risk factor–outcome pairs that meet the bar of convincing or probable evidence 
account for slightly less than 40% of the entire GBD strongly suggest that massive health 
gains could be expected from adoption of policies to avoid what is avoidable. Certainly, 
there are more risk factors yet to be discovered and some well known risks such as poverty 
and education have not yet been quantified according to this framework. But such unknowns 
should not impede a much greater response from countries and donors to implement policies 
that are known to work in controlling diseases and injuries, and which have demonstrably 
led to much improved health outcomes in countries that have adopted them.
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(Prof V Rahimi-Movaghar MD), Tehran University of Medical Sciences, Tehran, Iran; 
Federal University of São Paulo, São Paulo, Brazil (C P Ferri PhD); Institute of 
Gerontology, Academy of Medical Science, Kyiv, Ukraine (N Foigt PhD); James Cook 
University, Townsville, QLD, Australia (R C Franklin PhD); National Center for Disease 
Control and Public Health, Tiblisi, Georgia (Prof A Gamkrelidze PhD, I Khonelidze MPA, 
L Sturua PhD); Leras Afrique, Cotonou, Benin (F G Gankpé MD); CHU Hassan II, Fez, 
Morocco (F G Gankpé MD); Tuberculosis and Other Respiratory Diseases Division (E 
Gasana MPH), Rwanda Biomedical Centre, Kigali, Rwanda (N Sabin MD); Division of 
Human Nutrition, Wageningen University, Wageningen, Netherlands (J M Geleijnse PhD); 
Agence de Médecine Préventive, Paris, France (B D Gessner MD); Melbourne Health, 
Parkville, VIC, Australia (K B Gibney FRACP); Howard University, Washington, DC, USA 
(R F Gillum MD); College of Medicine, University of Hail, Hail, Saudi Arabia (I A M 
Ginawi MD); University Hospital of Dijon, Dijon, France (Prof M Giroud MD); IRCCS 
Mario Negri Institute for Pharmacological Research, Milan, Italy (G Giussani Biol D); 
Ministry of Labour, Health and Social Affairs, Tblisi, Georgia (K Goginashvili MPH); 
University of Massachusetts Boston, Boston, MA, USA (Prof P Gona PhD); Department of 
Public Health, Tokyo Women’s Medical University, Tokyo, Japan (A Goto MD); School of 
Medicine (R L Guerrant MD), Department of Anesthesiology (A S Terkawi MD), 
University of Virginia, Charlottesville, VA, USA; Saint James School of Medicine, 
Kralendijk, Netherlands Antilles (Prof H C Gugnani PhD); University of Bristol, Bristol, 
UK (Prof D Gunnell DSc); West Virginia Bureau for Public Health, Charleston, WV, USA 
(R Gupta MD); Fortis Escorts Hospital, Jaipur, India (R Gupta PhD); Karolinska Institute, 
Huddinge, Sweden (M Hagstromer PhD); Brandeis University, Waltham, MA, USA (Y A 
Halasa MS, B T Idrisov MD); Arabian Gulf University, Manama, Bahrain (Prof R R 
Hamadeh DPhil); Wayne County Department of Health and Human Services, Detroit, MI, 
USA (M Hammami MD); The University of Western Australia, Perth, WA, Australia (Prof 
G J Hankey MD); School of Public Health (Prof Y Hao PhD), Zhongshan Ophthalmic 
Center (Y Zheng MD), Sun Yat-sen University, Guangzhou, China; African Population and 
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(Prof K H Jacobsen PhD); UNFPA Asia and the Pacific Regional Office, Bangkok, Thailand 
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University School of Medicine, Shanghai, China (Prof M R Phillips MD); Department of 
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Roseline MD); University of Balamand, Beirut, Lebanon (Prof N E Karam MD); 
Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, 
Germany (A Karch MD); Hannover-Braunschweig Site, German Center for Infection 
Research, Braunschweig, Germany (A Karch MD); Malaria and Other Parasitic Diseases 
Division, Ministry of Health, Kigali City, Rwanda (C K Karema MSc); All India Institute of 
Medical Sciences, New Delhi, India (Prof G Karthikeyan DM, Prof V K Paul MD, M 
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School of Public Health and Family Medicine (R Matzopoulos PhD), University of Cape 
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MD); Cardiology, Hadassah Ein Kerem University Hospital, Jerusalem, Israel (Prof A 
Keren MD); Jordan University of Science and Technology, Irbid, Jordan (Prof Y S Khader 
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Medicine, Seoul, South Korea (Prof Y Khang MD); Federal University of Rio Grande do 
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University College, Johor, Malaysia (Y Kim PhD); Simmons College, Boston, MA, USA (R 
W Kimokoti MD); University of Canberra, Canberra, ACT, Australia (Y Kinfu PhD); 
University of Cincinnati, Cincinnati, OH, USA (Prof B M Kissela MD); National Cerebral 
and Cardiovascular Center, Suita, Japan (Y Kokubo PhD); Center for Community 
Empowerment, Health Policy and Humanities (S Kosen MD), National Institute of Health 
Research and Development, Ministry of Health Indonesia, Jakarta, Indonesia (T S Warouw 
PhD); Research Center of Neurology, Moscow, Russia (M Kravchenko PhD, Prof Y Y 
Varakin MD); Oregon Health and Science University, Portland, OR, USA (S Krishnaswami 
MD); University of Montreal, Montreal, QC, Canada (Prof B Kuate Defo PhD); Erasmus 
MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Prof E J Kuipers PhD, 
S Polinder MS); Rajrajeswari Medical College & Hospital, Bangalore, India (Prof C 
Kulkarni MD); Arkansas State University, State University, AR, USA (V S Kulkarni PhD); 
Boston Medical Center, Boston, MA, USA (G F Kwan MD); Fourth View Consulting, 
Tallinn, Estonia (T Lai PhD); School of Dentistry and Oral Health, Griffith University, Gold 
Coast, QLD, Australia (Prof R Lalloo PhD); Australian Research Centre for Population Oral 
Health, School of Dentistry, University of Adelaide, Adelaide, SA, Australia (Prof R Lalloo 
PhD); Disability Prevention Research Centre (T Lallukka PhD), Finnish Institute of 
Occupational Health, Helsinki, Finland (R Shiri PhD); Faculty of Medicine, University of 
Helsinki, Helsinki, Finland (T Lallukka PhD); Institute of Health Policy and Development 
Studies, National Institutes of Health, Manila, Philippines (Prof H Lam PhD); National 
Cancer Institute, Rockville, MD, USA (Q Lan PhD); Help Me See Inc, New York, NY, 
USA (V C Lansingh PhD); Instituo Mexicano de Oftalmologia, Queretaro, Mexico (V C 
Lansingh PhD); Servicio de Neurologia, Clinica Alemana, Universidad del Desarrollo, 
Santiago, Chile (P M Lavados MD); Instituto Nacional de Epidemiología “Dr Juan H Jara”, 
Mar del Plata, Argentina (Prof A E Lawrynowicz MPH); Nova Southeastern University 
College of Optometry, Fort Lauderdale, FL, USA (J L Leasher OD); Korea University, 
Seoul, South Korea (Prof J Lee PhD, S Yoon PhD); Tuscany Regional Centre for 
Occupational Injuries and Diseases, Florence, Italy (M Levi MD); Anolinx LLC, Salt Lake 
City, UT, USA (Y Li PhD); National Office for Maternal and Child Health Surveillance, 
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PhD); Ministry of Health Singapore, Singapore (S Ma PhD, H P Phua MSc); Saw Swee 
Hock School of Public Health, National University of Singapore, Singapore (S Ma PhD); 
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Tehran, Iran (Prof R Malekzadeh MD); Shiraz University of Medical Sciences, Shiraz, Iran 
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Marape PhD); Queen Mary University of London, London, UK (Prof W Marcenes PhD); 
Pereleman School of Medicine (P A Meaney MD), University of Pennsylvania, 
Philadelphia, PA, USA (D J Margolis PhD, D H Silberberg MD); Dalhousie University, 
Halifax, NS, Canada (Prof R V Martin PhD); University of the East Ramon Magsaysay 
Memorial Medical Center, Quezon City, Philippines (M B Marzan MSc); Ministry of Public 
Health, Kabul, Afghanistan (M T Mashal PhD); University of York, York, UK (A J Mason-
Jones PhD); Automotive Industry Development Centre Eastern Cape, Port Elizabeth, South 
Africa (T T Mazorodze MA); EmergentCorp, Belize City, Belize (A C McKay PhD); 
Children’s Hospital of Philadelphia, Philadelphia, PA, USA (P A Meaney MD); Janakpuri 
Superspecialty Hospital, New Delhi, India (Prof M Mehndiratta DM); Thomas Jefferson 
University, Philadelphia, PA, USA (M Meltzer MD); United Nations Population Fund, 
Lima, Peru (W Mendoza MD); Department of Neurology, Helsinki University Central 
Hospital, Helsinki, Finland (A Meretoja PhD); Ifakara Health Institute, Bagamoyo, Tanzania 
(F Apolinary Mhimbira MS); Pacific Institute for Research & Evaluation, Calverton, MD, 
USA (T R Miller PhD); Curtin University Centre for Population Health, Perth, WA, 
Australia (T R Miller PhD); University of Ottawa, Ottawa, ON, Canada (E J Mills PhD); 
Population Education Resource Centre, Department of Continuing and Adult Education and 
Extension Work, SNDT Women’s University, Mumbai, India (S Mishra PhD); Department 
of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Malaysia 
(Prof N Mohamed Ibrahim MRCP); University of Salahaddin, Erbil, Iraq (K A Mohammad 
PhD); University of Papua New Guinea, Boroko, Papua New Guinea (Prof G L Mola MD); 
Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Trieste, Italy (L Monasta 
DSc, M Montico MSc, L Ronfani PhD); University of North Texas, Denton, TX, USA (Prof 
A R Moore PhD); International Laboratory for Air Quality and Health (Prof L Morawska 
PhD), Institute of Health and Biomedical Innovation (R E Norman PhD), Queensland 
University of Technology, Brisbane, QLD, Australia; National Center for Child Health and 
Development, Setagaya, Japan (R Mori PhD); Department of Medicine (Prof M Tsilimbaris 
PhD), University of Crete, Heraklion, Greece (J Moschandreas PhD); Egerton University, 
Egerton, Kenya (W N Moturi PhD); Competence Center Mortality-Follow-Up of the 
German National Cohort (A Werdecker Dipl.oec.troph.); Federal Institute for Population 
Research, Wiesbaden, Germany (Prof U O Mueller PhD, R Westerman PhD); Okinawa 
Chubu Hospital, Okinawa, Japan (M Mukaigawara MD); American University of Beirut 
Medical Center, Beirut, Lebanon (Prof Z Nahas MD); University of KwaZulu-Natal, 
Durban, South Africa (Prof K S Naidoo PhD); Azienda Ospedaliera Papa Giovanni XXIII, 
Bergamo, Italy (Prof L Naldi MD); Ministry of Health, Suva, Fiji (D Nand MPH); Suraj Eye 
Institute, Nagpur, India (Prof V Nangia MD); The George Institute for Global Health, 
Sydney, NSW, Australia (B Neal PhD); Faculty of Medicine, Fez, Morocco (Prof C Nejjari 
PhD); University of Oslo, Oslo, Norway (S P Neupane PhD); Kilifi, Kenya (Prof C R 
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Ngalesoni MSc); East African Community Health Research Commission, Kigali, Rwanda (J 
D Ngirabega PhD); Hospital Universitari de Bellvitge, L’Hospitalet, Spain (J M Nolla PhD); 
Deakin University, Melbourne, VIC, Australia (S Nolte PhD); Department of Global Public 
Health and Primary Care (Prof S E Vollset MD), University of Bergen, Bergen, Norway 
(Prof O F Norheim PhD); Department of Clinical Sciences, Lund University, Lund, Sweden 
(Prof B Norrving PhD); Makerere University, Kampala, Uganda (L Nyakarahuka MPH); 
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Nigeria (B O Olusanya PhD); Lira District Local Government, Lira Municipal Council, 
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Pagcatipunan Jr MD); Christian Medical College Ludhiana, Ludhiana, India (J D Pandian 
DM); Kosin University College of Medicine, Busan, South Korea (E Park PhD); Unit on 
Anxiety & Stress Disorders (Prof D J Stein MD), South African Medical Research Council, 
Cape Town, South Africa (Prof C D Parry PhD); Stellenbosch University, Cape Town, 
South Africa (Prof C D Parry PhD, Prof S Seedat PhD); Independent Researcher, Boroko, 
Papua New Guinea (B I Pavlin MD); Economics Institute, Belgrade, Serbia (L Pejin Stokic 
MSc); REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, 
Faculdade de Farmácia, Universidade do Porto, Porto, Portugal (Prof D M Pereira PhD); 
National Institute of Respiratory Diseases, Mexico City, Mexico (Prof R Perez-Padilla MD); 
Hopsital Universitario Cruces, OSI EE-Cruces, Baracaldo, Spain (F Perez-Ruiz PhD); 
Biocruces Health Research Institute, Baracaldo, Spain (F Perez-Ruiz PhD); IRCCS Mario 
Negri Institute for Pharmacological Research, Bergamo, Italy (N Perico MD, Prof G 
Remuzzi MD, M Trillini MD); Washington State Department of Health, Kent, WA, USA (S 
A L Perry MSCE); Postgraduate Medical Institute, Lahore, Pakistan (A Pervaiz MHA); 
Flinders University, Adelaide, SA, Australia (Prof K Pesudovs PhD); Aalborg University, 
Aalborg Esst, Denmark (C B Peterson PhD); Health Metrics Unit, Gothenburg, Sweden 
(Prof M Petzold PhD); The University of the Witwatersrand, Johannesburg, South Africa 
(Prof M Petzold PhD); Emory University, Atlanta, GA, USA (Prof M R Phillips MD); 
Section Exposure Assessment and Environmental Health Indicators, Federal Environment 
Agency, Berlin, Germany (D Plass Dr PH); Montreal Children’s Hospital, McGill 
University, Montreal, QC, Canada (Prof D Poenaru MD); MyungSung Medical College, 
Addis Ababa, Ethiopia (Prof D Poenaru MD); University of Newcastle, Callaghan, NSW, 
Australia (Prof C D Pond PhD); Brigham Young University, Provo, UT, USA (Prof C Pope 
PhD); Centre for Addiction and Mental Health, Toronto, ON, Canada (S Popova PhD, Prof J 
Rehm PhD); The Fred Hollows Foundation, Sydney, NSW, Australia (N M Prasad DO); 
College of Pharmacy, University of Illinois, Chicago, IL, USA (D M Qato PhD); Contech 
International Health Consultants, Lahore, Pakistan (A Rafay MS, Prof S M Rana PhD); 
Contech School of Public Health, Lahore, Pakistan (A Rafay MS, Prof S M Rana PhD); 
Hamad Medical Corporation, Doha, Qatar (S Ur Rahman FCPS); University of Missouri, 
Columbia, MO, USA (M Raju PhD); WHO Regional Office for Europe, Copenhagen, 
Denmark (I Rakovac PhD); Warren Alpert Medical School, Brown University, Providence, 
RI, USA (M Rao BA); Center for Disease Analysis, Louisville, CO, USA (H Razavi PHD); 
Suez Canal University, Ismailia, Egypt (Prof A H Refaat PhD); Hospital das Clinica (Prof A 
L Ribeiro PhD), Escola de Enfermagem (Prof G Velasquez-Melendez PhD), Universidade 
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Federal de Minas Gerais, Belo Horizonte, Brazil, Department of Clinical Neurological 
Sciences, London Health Sciences Centre, University of Western Ontario, London, ON, 
Canada (P M Riccio MD, L A Sposato MD); George Washington University, Washington, 
DC, USA (A Riederer DSc); MRC Unit, Fajara, The Gambia (A Roca PhD); Mid Sweden 
University, Stersund, Sweden (Prof A Rodriguez PhD); International Agency for Research 
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Sciences, Dar es Salaam, Tanzania (G M Ruhago MA, B F Sunguya MSc); Miller School of 
Medicine, University of Miami, Miami, FL, USA (R L Sacco MD); Queensland Centre for 
Mental Health Research, The Park Centre for Mental Health, Brisbane, QLD, Australia (S 
Saha PhD); Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia (R 
Sahathevan PhD); Calvary Healthcare Bruce, Canberra, ACT, Australia (R Sahathevan 
PhD); Case Western Reserve University, Cleveland, OH, USA (J R Sanabria MD); Cancer 
Treatment Centers of America—RFU Chicago Medical School, North Chicago, IL, USA (J 
R Sanabria MD); Centre on Ageing and Mobility, University of Zurich and City Hospital 
Waid, Zurich, Switzerland (L Sanchez-Riera PhD); School of Public Health, University of 
Maryland, College Park, MD, USA (A Sapkota PhD); Dartmouth Hitchcock Medical Center 
(J E Saunders MD), Dartmouth College, Lebanon, NH, USA (S Soneji PhD); Marshall 
University, Huntington, WV, USA (M Sawhney PhD); Novartis Turkey, Istanbul, Turkey 
(M I Saylan PhD); Federal University of Santa Catarina, Florianópolis, Brazil (I J C 
Schneider PhD); University of Alabama at Birmingham, Birmingham, AL, USA (D C 
Schwebel PhD, J A Singh MD); University of Colorado, Aurora, CO, USA (B Serdar PhD); 
University of Bath, Bath, UK (G Shaddick PhD); University of Pittsburgh Medical Center, 
Pittsburgh, PA, USA (S Shangguan MD); Tachikawa Hospital, Tokyo, Japan (Y Shinohara 
PhD); School of Health Sciences, University of Tampere, Tampere, Finland (R Shiri PhD); 
Washington State University, Spokane, WA, USA (K Shishani PhD); Health and Life 
Sciences, Northumbria University, Newcastle upon Tyne, UK (I Shiue PhD); Alzheimer’s 
Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, Scotland, UK (I 
Shiue PhD); Reykjavik University, Reykjavik, Iceland (I D Sigfusdottir PhD); International 
Institute for Population Sciences, Mumbai, India (A Singh PhD); Stavanger University 
Hospital, Stavanger, Norway (K Søreide PhD); Faculty of Medicine and Health Sciences, 
Universiti Tunku Abdul Rahman, Kajang, Cheras, Malaysia (C T Sreeramareddy MPH); 
Griffith University, Southport, QLD, Australia (N J C Stapelberg FRANZCP); Attikon 
University Hospital, Athens, Greece (V Stathopoulou PhD); University Hospital Munich, 
Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, 
Munich, Germany (N Steckling MSc); Alexandra General Hospital of Athens, Athens, 
Greece (K Stroumpoulis PhD); Centre Hospitalier Public du Cotentin, Cherbourg, France (K 
Stroumpoulis PhD); National Institute for Research in Tuberculosis, Chennai, India (S 
Swaminathan MD); Northwestern University, Chicago, IL, USA (M Swaroop MD, Dr Y 
Yano MD); University of California, Irvine, CA, USA (Prof B L Sykes PhD); University of 
Illinois at Urbana-Champaign, Champaign, IL, USA (K M Tabb PhD); Ministry of Health, 
MINSANTE, Yaounde, Cameroon (R T Talongwa); Chaim Sheba Medical Center, Tel 
Hashomer, Israel (Prof D Tanne MD); Tel Aviv University, Tel Aviv, Israel (Prof D Tanne 
MD); Westchester Medical Center, Valhalla, NY, USA (M Tavakkoli MD); Outcomes 
Research Consortium, Cleveland, OH, USA (A S Terkawi MD); Department of 
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Topouzis PhD); Le Bonheur Children’s Hospital, Memphis, TN, USA (Prof J A Towbin 
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PhD); National Institute for Public Health and the Environment, Bilthoven, Netherlands (C 
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University, Arlington, VA, USA (M T Wallin MD); VA Medical Center, Washington, DC, 
USA (M T Wallin MD); Beijing Neurosurgical Institute, Beijing, China (Prof W Wang 
MD); Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, 
Australia (R G Weintraub MB, BS); University of California, Davis, CA, USA (K Wessells 
PhD); German National Cohort Consortium, Heidelberg, Germany (R Westerman PhD); 
Wayne State University, Detroit, MI, USA (Prof J D Wilkinson MD); University of 
Nottingham, Nottingham, UK (Prof H C Williams PhD); Institute of Public Health, 
University of Gondar, Gondar, Ethiopia (S M Woldeyohannes MPH); Ateneo School of 
Medicine and Public Health, Manila University, Pasig City, Philippines (J Q Wong MD); 
Royal Cornwall Hospital, Truro, Cornwall, UK (Prof A D Woolf FRCP); Jinling Hospital, 
Nanjing University School of Medicine, Nanjing, China (Prof G Xu PhD); Duke Kunshan 
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Research in context
Evidence before this study
As part of the Global Burden of Disease (GBD) 2010 study a revision of the global 
comparative risk assessment was undertaken, with an expanded list of 67 risks and risk 
clusters by 21 world regions, and comparable estimates made for the time period 1990–
2010. Quantification of the burden that can be attributed to risk factors is important 
information to set priorities in prevention.
Added value of this study
The GBD 2013 comparative risk assessment is a further update to the GBD 2010 study in 
several ways: (1) addition of new risk factors (handwashing practices, occupational 
exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low 
glomerular filtration rate); (2) new data for exposure; (3) assumption of a lognormal 
rather than a normal distribution for most of the continuous risk factors to better represent 
the observed population distributions; (4) updates to the systematic reviews and meta-
analyses of relative risks; (5) aggregation of the burden at multiple levels of risk factors, 
including the combined effect of all GBD risk factors and aggregates of three large 
classes—ie, behavioural, environmental and occupational, and metabolic risk factors; (6) 
systematic inclusion of mediation between major risk factors in the quantification of the 
burden associated with joint risks; and (7) quantification of the risk burden for 188 
countries. Furthermore, several major improvements to specific risk factors were 
implemented, such as use of the latest analytical instruments for multilevel analysis of 
exposure (DisMod-MR), as well as production of burden estimates for 5-year intervals 
from 1990–2010 plus 2013.
Implications of all the available evidence
Comparative risk assessment enables policy makers to prioritise prevention by addressing 
the most important risk factors at the population level. The burden by aggregations of 
risk categories, such as air pollution or dietary risks, provides the broad view of 
investment priorities, whereras the size of burden for individual risks can inform the 
potential elements of a broader intervention package. In 2013, we explain 41% of burden 
by the 79 GBD risk factors with a slight increase since 1990. This proportion varies 
between 28% and 61% between countries, highlighting the importance of making country 
estimates as the opportunities for intervention will vary accordingly. Unless new risk 
factors are identified, the proportion of burden that is not explained by GBD risk factors 
is likely to be less amenable to primary prevention but more of a concern for curative or 
rehabilitative services.
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Figure 1. A more general causal web of the causes of health outcomes
Categories of causes included in this analysis shown in blue. GBD=Global Burden of 
Disease.
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Figure 2. Tree maps of global deaths (A) and global DALYs (B) for GBD level 2 causes for all 
ages, both sexes combined in 2013
The fraction of each cause attributable to all risk factors combined is shown with dark 
shading. DALYs=disability-adjusted life-years. GBD=Global Burden of Disease. Chr 
Resp=chronic respiratory diseases. Diab + Urog + Haem=diabetes, urogenital, blood, and 
endocrine diseases. Diar + LRI + Oth=diarrhoea, lower respiratory, and other common 
infectious diseases. HIV + TB=HIV/AIDS and tuberculosis. Mental=mental and substance 
use disorders. MSK=musculoskeletal disorders. Neuro=neurological disorders. Nutr 
Def=nutritional deficiencies. Oth NCD=other non-communicable diseases. Other group 
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I=other communicable, maternal, neonatal, and nutritional diseases. NTD + 
Malaria=neglected tropical diseases and malaria. Self-harm + IPV=self-harm and 
interpersonal violence. Trans Inj=transportation injuries. Unint Inj=unintentional injuries.
Page 48
Lancet. Author manuscript; available in PMC 2016 June 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Proportion of all-cause DALYs attributable to behavioural, environmental and 
occupational, and metabolic risk factors and their overlaps for all ages in 2013
DALYs=disability-adjusted life-years. ∩=interaction.
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Figure 4. Proportion of global all-cause DALYs attributable to behavioural, environmental and 
occupational, and metabolic risk factors and their overlaps, by age for both sexes combined in 
2013
DALYs=disability-adjusted life-years. ∩=interaction.
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Figure 5. Global DALYs attributed to level 2 risk factors in 2000 for both sexes combined (A) 
and global DALYs attributed to level 2 risk factors in 2013 for both sexes combined (B)
DALYs=disability-adjusted life-years.
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Figure 6. Global DALYs attributed to level 2 risk factors in 2013 for sub-Saharan Africa for 
both sexes combined
DALYs=disability-adjusted life-years.
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Figure 7. The 25 leading level 3 global risk factors for DALYs in both sexes combined in 2000 
and 2013
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Figure 8. Global maps for level 3 risk factors in 2013 of attributable DALYs for males (A) and 
females (B)
DALYs=disability-adjusted life-years. ATG=Antigua and Barbuda. VCT=Saint Vincent and 
the Grenadines. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-
Leste. TTO=Trinidad and Tobago. Isl=Islands.
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Figure 9. The ten leading level 3 risks in 2013 in terms of DALYs by location for both sexes 
combined
The 15 leading risk factors are coloured. Subopt=Suboptimal. Occ=occupational. 
DALYs=disability-adjusted life-years. Bone mineral density=low bone mineral density. 
Handwashing=no handwashing with soap. Int partner violence=intimate partner violence. 
Nuts and seeds=diet low in nuts and seeds. Occ ergonomic=occupational ergonomic factors. 
Particulate matter=ambient particulate matter pollution. Physical activity=low physical 
activity. Processed meat=diet high in processed meat. Subopt breastfeeding=suboptimal 
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breastfeeding. Sweetened beverages=diet high in sugar-sweetened beverages. 
Vegetables=diet low in vegetables.
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Table 1
GBD 2013 risk factor hierarchy, exposure definitions, theoretical minimum risk exposure 
level, and data representativeness index (DRI) for the entire period 1985–2013, pre-1998, 
1998–2005, and 2006–13
Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
All risk factors · · · · 100·0% 100·0% 100·0% 100·0%
Environmental and 
occupational risks
· · · · 100·0% 100·0% 100·0% 100·0%
  Unsafe water, sanitation,
 and handwashing
59·0% 72·3% 60·6% 80·3%
  Unsafe water source Proportion of 
households with 
access to different 
water sources 
(unimproved, 
improved except 
piped, piped water 
supply) and reported 
use of household 
water treatment 
methods (boiling or 
filtering; chlorinating 
or solar filtering; no 
treatment)
All households have access to 
water from a piped water supply 
that is also boiled or filtered 
before drinking
69·6% 84·2% 68·4% 91·8%
  Unsafe sanitation Proportion of 
households with 
access to different 
sanitation facilities 
(unimproved, 
improved except 
sewer, sewer 
connection)
All households have access to 
toilets with sewer connection
65·8% 81·6% 67·1% 91·1%
  No handwashing
  with soap
Proportion of 
individuals who wash 
their hands with soap 
and water after 
potential faecal 
contact
All individuals wash hands with 
soap and water after potential 
faecal contact
1·1% 10·1% 25·5% 29·3%
  Air pollution 100·0% 100·0% 100·0% 100·0%
  Ambient particulate
  matter pollution
Annual average daily 
exposure to outdoor 
air concentrations of 
particulate matter 
(PM) with an 
aerodynamic 
diameter smaller than 
2·5 μm, measured in 
μg/m3
Uniform distribution between 5·9 
μg/m3 and 8·7 μg/m3
99·5% 99·5% 99·5% 99·5%
  Household air pollution
  from solid fuels
Annual average daily 
exposure to 
household 
concentrations of 
particulate matter 
(PM) with an 
aerodynamic 
diameter smaller than 
2·5 μm, measured in 
μg/m3 from solid fuel 
use (coal, wood, 
charcoal, dung, and 
agricultural residues)
No households are exposed to 
excess indoor concentration of 
particles from solid fuel use 
(assuming concentration of 
particulate matters, aerodynamic 
diameter smaller than 2·5 μg/m3, 
measured in μg/m3 in no fuel use 
is consistent with a TMREL of 
5·9–8·7)
47·8% 83·3% 71·7% 94·2%
Lancet. Author manuscript; available in PMC 2016 June 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 59
Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
  Ambient ozone pollution Seasonal (3 month) 
hourly maximum 
ozone concentrations, 
measured in parts per 
billion (ppb)
Uniform distribution between 
33·3 μg/m3 and 41·9 μg/m3, 
according to minimum/5th 
percentile concentrations
100·0% 100·0% 100·0% 100·0%
  Other environmental risks 34·0% 38·8% 26·6% 49·5%
  Residential radon Average daily 
exposure to indoor air 
radon levels 
measured in 
becquerels (radon 
disintegrations per s) 
per cubic metre 
(Bq/m3)
10 Bq/m3, corresponding to the 
outdoor concentration of radon
19·7% 27·1% 11·7% 38·3%
  Lead exposure Blood lead levels in 
μg/dL of blood, bone 
lead levels in μg/g of 
bone
2 μg/dL, corresponding to lead 
levels in pre-industrial humans as 
natural sources of lead prevent the 
feasibility of zero exposure
29·3% 27·1% 20·2% 39·9%
  Occupational risks 56·4% 64·4% 55·3% 72·3%
  Occupational carcinogens · · · · 34·0% 56·9% 51·6% 62·8%
   Occupational exposure
   to asbestos
Proportion of the 
population with 
cumulative exposure 
to asbestos
No occupational exposure to 
asbestos
· · · · · · · ·
   Occupational exposure
   to arsenic
Proportion of the 
population ever 
exposed to arsenic at 
work/through their 
occupation
No occupational exposure to 
arsenic
· · · · · · · ·
   Occupational exposure
   to benzene
Proportion of the 
population ever 
exposed to benzene at 
work/through their 
occupation
No occupational exposure to 
benzene
· · · · · · · ·
   Occupational exposure
   to beryllium
Proportion of the 
population ever 
exposed to beryllium 
at work/through their 
occupation
No occupational exposure to 
beryllium
· · · · · · · ·
   Occupational exposure
   to cadmium
Proportion of the 
population ever 
exposed to cadmium 
at work/through their 
occupation
No occupational exposure to 
cadmium
· · · · · · · ·
   Occupational exposure
   to chromium
Proportion of the 
population ever 
exposed to chromium 
at work/through their 
occupation
No occupational exposure to 
chromium
· · · · · · · ·
   Occupational exposure
   to diesel
   engine exhaust
Proportion of the 
population ever 
exposed to diesel 
engine exhaust at 
work/through their 
occupation
No occupational exposure to 
diesel engine exhaust
· · · · · · · ·
   Occupational exposure
   to second-hand smoke
Proportion of the 
population ever 
exposed to second-
hand smoke at work/
through their 
occupation
No occupational exposure to 
second-hand smoke
· · · · · · · ·
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
   Occupational exposure
   to formaldehyde
Proportion of the 
population ever 
exposed to 
formaldehyde at 
work/through their 
occupation
No occupational exposure to 
formaldehyde
· · · · · · · ·
   Occupational exposure
   to nickel
Proportion of the 
population ever 
exposed to nickel at 
work/through their 
occupation
No occupational exposure to 
nickel
· · · · · · · ·
   Occupational exposure
   to polycyclic aromatic
   hydrocarbons
Proportion of the 
population ever 
exposed to polycyclic 
aromatic 
hydrocarbons at 
work/through their 
occupation
No occupational exposure
   to polycyclic aromatic
   hydrocarbons
· · · · · · · ·
   Occupational exposure
   to silica
Proportion of the 
population ever 
exposed to silica at 
work/through their 
occupation
No occupational exposure to silica · · · · · · · ·
   Occupational exposure
   to sulphuric acid
Proportion of the 
population ever 
exposed to sulphuric 
acid at work/through 
their occupation
No occupational exposure to 
sulphuric acid
· · · · · · · ·
   Occupational exposure
   to trichloroethylene
Proportion of the 
population ever 
exposed to 
trichloroethylene at 
work/through their 
occupation
No occupational exposure to 
trichloroethylene
· · · · · · · ·
  Occupational asthmagens Proportion of the 
population currently 
exposed to 
asthmagens at work/
through their 
occupation
Background asthmagen exposures 41·0% 37·2% 36·2% 52·7%
  Occupational particulate
  matter, gases, and fumes
Proportion of the 
population ever 
exposed to 
particulates, gases, or 
fumes at work/
through their 
occupation
No occupational exposure to 
particulates, gases, or fumes
34·0% 56·9% 51·6% 62·8%
  Occupational noise Proportion of the 
population ever 
exposed to noise 
greater than 85 
decibels at work/
through their 
occupation
Background noise exposure 34·0% 56·9% 51·6% 62·8%
  Occupational injuries Proportion of the 
population at risk to 
injuries related to 
work/through their 
occupation
The rate of injury deaths per 100 
000 person-years is zero
5·3% 17·0% 18·6% 20·7%
  Occupational ergonomic
  factors
Proportion of the 
population who are 
exposed to 
ergonomic risk 
All individuals have the 
ergonomic factors of clerical and 
related workers
32·4% 58·5% 48·9% 63·3%
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
factors for low back 
pain at work/through 
their occupation
Behavioural risks · · · · 100·0% 100·0% 100·0% 100·0%
  Child and maternal
 malnutrition
97·3% 97·9% 96·8% 98·9%
  Suboptimal breastfeeding 44·7% 68·1% 55·9% 78·2%
   Non-exclusive
   breastfeeding
Proportion of 
children younger than 
6 months who receive 
predominant, partial, 
or no breastfeeding
All children are exclusively 
breastfed for first 6 months of life
· · · · · · · ·
   Discontinued
   breastfeeding
Proportion of 
children aged 6–23 
months who do not 
receive any 
breastmilk
All children continue to receive 
breast milk until 2 years of age
· · · · · · · ·
  Childhood undernutrition 79·3% 72·3% 59·6% 86·7%
   Childhood underweight Proportion of 
children less than −3 
SDs, −3 to −2 SDs, 
and −2 to −1 SDs of 
the WHO 2006 
standard weight-for-
age curve
All children are above −1 SD of 
the WHO 2006 standard weight-
for-age curve
· · · · · · · ·
   Childhood wasting Proportion of 
children less than −3 
SDs, −3 to −2 SDs, 
and −2 to −1 SDs of 
the WHO 2006 
standard weight-for-
length curve
All children are above −1 SD of 
the WHO 2006 standard weight-
for-height curve
· · · · · · · ·
   Childhood stunting Proportion of 
children less than −3 
SDs, −3 to −2 SDs, 
and −2 to −1 SDs of 
the WHO 2006 
standard height-for-
age curve
All children are above −1 SD of 
the WHO 2006 standard height-
for-height curve
· · · · · · · ·
  Iron deficiency Peripheral blood 
haemoglobin 
concentration in g/L
Country specific 40·4% 34·0% 22·3% 45·7%
  Vitamin A deficiency Proportion of 
children aged 28 days 
to 5 years with serum 
retinol concentration 
<0·7 μmol/L
No childhood vitamin A 
deficiency
22·9% 53·7% 45·7% 58·5%
  Zinc deficiency Proportion of the 
population with 
inadequate zinc 
intake versus loss
No inadequate zinc intake 89·9% 89·9% 91·0% 91·0%
  Tobacco smoke 34·0% 91·0% 95·7% 98·4%
  Smoking Proportion of the 
population with 
cumulative exposure 
to tobacco smoking; 
proportion of the 
population who 
currently smoke
100% of population is lifelong 
nonsmokers
34·0% 89·4% 93·6% 96·3%
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
  Second-hand smoke Average daily 
exposure to indoor air 
particulate matter 
from second-hand 
smoke with an 
aerodynamic 
diameter smaller than 
2·5 μg, measured in 
μg/m3
No second-hand smoke exposure 8·5% 69·1% 87·2% 92·6%
  Alcohol and drug use 100·0% 100·0% 100·0% 100·0%
  Alcohol use Average daily 
alcohol consumption 
of pure alcohol 
(measured in g/day) 
in current drinkers 
who had consumed 
alcohol during the 
past 12 months; binge 
drinking defined as 
proportion of the 
population reporting 
binge consumption of 
at least 60 g for males 
and 48 g for females 
of pure alcohol on a 
single occasion
No alcohol consumption 100·0% 100·0% 100·0% 100·0%
  Drug use Proportion of the 
population dependent 
on opioids, cannabis, 
cocaine, or 
amphetamines; 
proportion of the 
population who have 
ever injected drugs
No use 28·7% 50·5% 54·3% 67·0%
  Dietary risks 89·9% 93·1% 92·0% 94·1%
  Diet low in fruits Average daily 
consumption of fruits 
(fresh, frozen, 
cooked, canned, or 
dried, excluding fruit 
juices and salted or 
pickled fruits)
Consumption of fruit between 200 
g and 400 g per day
19·1% 38·8% 22·9% 56·4%
  Diet low in vegetables Average daily 
consumption of 
vegetables (fresh, 
frozen, cooked, 
canned, or dried 
vegetables, including 
legumes but 
excluding salted or 
pickled vegetables, 
juices, nuts and 
seeds, and starchy 
vegetables such as 
potatoes or corn)
Consumption of vegetables 
between 350 g and 450 g per day
88·8% 92·6% 90·4% 93·6%
  Diet low in whole grains Average daily 
consumption of 
whole grains (bran, 
germ, and endosperm 
in their natural 
proportion) from 
breakfast cereals, 
bread, rice, pasta, 
biscuits, muffins, 
Consumption of whole grains 
between 100 g and 150 g per day
87·8% 89·9% 89·4% 89·9%
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
tortillas, pancakes, 
and other sources
  Diet low in nuts and seeds Average daily 
consumption of nut 
and seed foods
Consumption of nuts and seeds 
between 12 g and 20 g per day
78·7% 85·1% 83·0% 86·7%
  Diet low in milk Average daily 
consumption of milk, 
including non-fat, 
low-fat, and full-fat 
milk, excluding soy 
milk and other plant 
derivatives
Consumption of milk between 
425 g and 475 g per day
88·8% 91·0% 89·4% 91·0%
  Diet high in red meat Average daily 
consumption of red 
meat (beef, pork, 
lamb, and, goat but 
excluding poultry, 
fish, eggs, and all 
processed meats)
Consumption of red meat between 
11·4 g and 17·1 g per day
88·8% 91·0% 89·4% 91·0%
  Diet high in processed
  meat
Average daily 
consumption of meat 
preserved by 
smoking, curing, 
salting, or addition of 
chemical 
preservatives
Consumption of processed meat 
between 0 g and 14·3 g per day
14·4% 24·5% 6·9% 28·2%
  Diet high in sugar-
  sweetened beverages
Average daily 
consumption of 
beverages with ≥50 
kcal per 226·8 g 
serving, including 
carbonated 
beverages, sodas, 
energy drinks, and 
fruit drinks, but 
excluding 100% fruit 
and vegetable juices
Consumption of sugar-sweetened 
beverages between 0 g and 64·3 g 
per day
13·8% 23·9% 7·4% 27·1%
  Diet low in fibre Average daily intake 
of fibre from all 
sources including 
fruits, vegetables, 
grains, legumes, and 
pulses
Consumption of fibre between 28 
g and 32 g per day
12·8% 19·7% 9·0% 27·1%
  Diet suboptimal in
  calcium
Average daily intake 
of calcium from all 
sources, including 
milk, yogurt, and 
cheese
Consumption of calcium between 
0 g and 0·77 g per day
15·4% 20·7% 11·2% 31·4%
  Diet low in seafood
  omega-3 fatty
  acids
Average daily intake 
of eicosapentaenoic 
acid and 
docosahexaenoic acid
Consumption of seafood omega-3 
fatty acids between 200 mg and 
300 mg per day
87·7% 90·4% 88·8% 90·4%
  Diet low in
  polyunsaturated fatty
  acids
Average daily intake 
of omega-6 fatty 
acids from all 
sources, mainly 
liquid vegetable oils, 
including soybean 
oil, corn oil, and 
safflower oil
Consumption of polyunsaturated 
fatty acids between 10% and 15% 
of total daily energy
9·0% 12·2% 5·3% 17·0%
  Diet high in trans fatty
  acids
Average daily intake 
of trans fat from all 
sources, mainly 
partially 
Consumption of trans fatty acids 
between 0% and 0·8% of total 
daily energy
8·5% 42·0% 42·0% 42·0%
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
hydrogenated 
vegetable oils and 
ruminant products
  Diet high in sodium 24 h urinary sodium 
measured in mg per 
day
Consumption of sodium between 
1 g and 5 g per day
25·0% 18·6% 11·7% 33·5%
  Sexual abuse and violence 17·6% 45·7% 53·2% 66·0%
  Childhood sexual abuse Proportion of the 
population who have 
ever experienced one 
or more acts of 
childhood sexual 
abuse, defined as the 
experience with an 
older person of 
unwanted non-
contact, contact 
abuse, or intercourse, 
when aged 15 years 
or younger
No childhood sexual abuse 9·0% 25·5% 17·6% 37·8%
  Intimate partner violence Proportion of the 
population who have 
ever experienced one 
or more acts of 
physical or sexual 
violence by a present 
or former intimate 
partner since age 15 
years
No intimate partner violence 13·8% 44·1% 47·3% 61·7%
  Unsafe sex Proportion of the 
population with 
exposure to sexual 
encounters that 
convey the risk of 
disease
No exposure to a disease agent 
through sex
14·4% 17·0% 43·1% 43·6%
  Low physical activity Average weekly 
physical activity at 
work, home, 
transport-related, 
and recreational 
measured by 
metabolic 
equivalent (MET) 
mins per week
Highly active, ≥8000 MET min 
per week
0·0% 50·5% 31·4% 63·3%
  Metabolic risks · · · · 68·1% 89·9% 87·8% 97·9%
  High fasting plasma
  glucose
Serum fasting plasma 
glucose, measured in 
mmol/L
4·8–5·4 31·4% 38·3% 23·4% 54·3%
  High total cholesterol Serum total 
cholesterol, measured 
in mmol/L
3·0–4·8 23·9% 27·7% 22·3% 46·8%
  High systolic blood
  pressure
Systolic blood 
pressure, measured in 
mm Hg
107–119 36·2% 45·7% 36·2% 71·8%
  High body-mass index Body-mass index, 
measured in kg/m2
21–23 57·4% 87·8% 86·2% 97·3%
  Low bone mineral density Standardised mean 
bone mineral density 
values measured at 
the femoral neck in 
g/cm2
99th percentile of NHANES 
2005–10 by age and sex
14·9% 19·7% 6·9% 25·5%
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Exposure definition Theoretical minimum risk 
exposure level
Data representativeness index
<1998 1998–2005 2006–13 Total
  Low glomerular filtration
  rate
Proportion of the 
population with a 
GFR <60 mL per min 
per 1·73 m2, and 
excluding end-stage 
renal disease
>60 mL per min per 1·73 m2 5·3% 12·2% 14·4% 21·8%
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Table 2
The age-standardised PAF attributable to the joint distribution of all risk factors for all 
ages, both sexes combined for each GBD level 1 and level 2 cause and all causes for 2013
Deaths 2013 YLLs 2013 YLDs 2013 DALYs 2013
All causes 57·2% (55·8–58·5) 47·9% (46·6–49·0) 27·6% (26·6–28·5) 41·6% (40·1–43·0)
Communicable, maternal, neonatal, and nutritional 
diseases
44·1% (42·4–46·0) 40·8% (39·0–42·7) 51·8% (49·0–54·1) 42·3% (40·6–44·1)
 HIV/AIDS and tuberculosis 59·8% (55·7–63·9) 58·5% (55·3–62·0) 62·5% (58·8–66·0) 58·7% (55·5–62·2)
 Diarrhoea, lower respiratory, and other common 
infectious diseases
62·4% (60·0–64·8) 70·4% (67·6–73·0) 50·1% (41·3–57·6) 69·3% (66·5–71·9)
 Neglected tropical diseases and malaria 0 0 0 0
 Maternal disorders 6·1% (2·7–9·1) 6·1% (2·8–9·1) 1·4% (0·5–2·5) 5·8% (2·6–8·6)
 Neonatal disorders 0 0 0 0
 Nutritional deficiencies 56·8% (50·2–65·2) 78·2% (73·7–82·7) 94·2% (93·2–95·0) 87·0% (84·6–89·3)
 Other communicable, maternal, neonatal, and 
nutritional diseases
33·0% (23·5–43·3) 47·6% (35·1–59·6) 38·0% (32·8–46·1) 46·5% (35·3–57·6)
Non-communicable diseases 64·0% (62·3–65·7) 58·9% (56·8–60·7) 23·1% (21·8–24·3) 43·8% (41·1–46·3)
 Neoplasms 45·0% (42·1–47·7) 42·5% (39·8–45·1) 32·0% (29·9–34·0) 42·1% (39·4–44·7)
 Cardiovascular diseases 88·5% (86·3–90·5) 88·7% (87·4–90·0) 76·5% (73·5–79·5) 87·9% (86·5–89·3)
 Chronic respiratory diseases 49·3% (43·2–54·7) 45·3% (39·6–50·3) 44·1% (39·3–49·2) 44·9% (40·2–49·2)
 Cirrhosis 57·3% (50·2–62·1) 56·8% (49·1–61·5) 44·3% (40·7–47·3) 56·6% (49·0–61·3)
 Digestive diseases 2·0% (1·0–2·8) 2·7% (1·4–3·8) 1·3% (0·7–1·8) 2·4% (1·3–3·3)
 Neurological disorders 0·6% (0·4–0·7) 1·9% (1·2–2·5) 1·3% (0·8–1·7) 1·5% (1·0–1·9)
 Mental and substance use disorders 93·7% (90·8–94·8) 95·3% (93·1–96·0) 17·6% (16·0–19·4) 22·8% (20·7–25·4)
 Diabetes, urogenital, blood, and endocrine diseases 77·6% (73·0–80·9) 64·5% (53·1–72·7) 64·8% (60·0–68·9) 64·5% (57·6–69·6)
 Musculoskeletal disorders 0 0 19·9% (17·9–21·9) 19·4% (17·5–21·4)
 Other non-communicable diseases 0 0 6·3% (5·4–7·3) 4·4% (3·6–5·2)
Injuries 26·9% (25·4–28·6) 23·3% (21·7–25·1) 38·7% (35·1–41·3) 25·8% (24·0–27·6)
 Transport injuries 36·8% (34·3–39·5) 34·0% (31·2–37·0) 44·3% (42·1–46·7) 35·4% (32·7–38·4)
 Unintentional injuries 20·0% (17·8–21·9) 12·3% (10·8–14·0) 43·3% (41·5–45·2) 19·1% (16·8–21·4)
 Self-harm and interpersonal violence 27·9% (25·2–31·0) 28·2% (25·4–31·4) 26·6% (24·9–28·7) 28·1% (25·4–31·3)
 Forces of nature, war, and legal intervention 0·3% (0·2–0·3) 0·1% (0·1–0·2) 1·5% (0·9–2·4) 1·0% (0·6–1·5)
Data are % (95% UI). YLLs=years of life lost. YLDs=years lived with disability. DALYs=disability-adjusted life-years. PAF=population 
attributable fraction.
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Table 3
Global, all-age, all-cause deaths, and DALYs for both sexes combined attributable to each 
risk factor in 1990 and 2013 with 95% uncertainty intervals
1990 
deaths (in 
thousands)
2013 
deaths (in 
thousands)
Median 
percent 
change 
deaths
Median 
percent 
change of 
age-
standardised 
deaths PAF
1990 
DALYs (in 
thousands)
2013 
DALYs (in 
thousands)
Median 
percent 
change 
DALYs
Median 
percent 
change of 
age-
standardised 
DALYs PAF
All risk factors 25 085 (24 
385 to 25 
821)
30 839 (29 
719 to 31 
949)
23·0% 
(19·0 to 
27·3)
0·6% (−1·0 
to 2·0)
1 035 987 
(980 813 to 
1 092 478)
996 554 
(927 157 to 
1 072 340)
−3·8% 
(−7·7 to 
−0·1)
−3·8% (−6·0 
to −1·8)
Environmental risks 8492 (8036 
to 8953)
8181 (7651 
to 8726)
−3·7% 
(−9·6 to 
2·4)
−15·5% 
(−19·8 to 
11·1)
400 345 
(374 489 to 
424 432)
289 517 
(265 778 to 
312 094)
−27·7% 
(−32·1 
to 
−23·2)
−22·6% 
(−26·1 to 
−19·1)
 Unsafe water,
 sanitation, and
 handwashing
2727 (2530 
to 2952)
1399 (1237 
to 1576)
−48·8% 
(−53·6 
to 
−43·7)
−44·9% 
(−49·6 to 
−40·0)
190 423 
(174 685 to 
208 033)
83 867 (72 
879 to 95 
568)
−56·0% 
(−60·6 
to 
−50·9)
−45·6% 
(−50·8 to 
−40·1)
  Unsafe water source 2434 (1971 
to 2763)
1246 (989 
to 1464)
−48·8% 
(−53·7 
to 
−43·9)
−45·0% 
(−49·7 to 
−40·1)
170 053 
(137 216 to 
193 963)
75 125 (59 
952 to 89 
756)
−55·9% 
(−60·4 
to 
−50·8)
−45·5% 
(−50·7 to 
−40·0)
  Unsafe sanitation 1785 (1613 
to 1959)
816 (707 to 
921)
−54·4% 
(−58·8 
to 
−49·8)
−51·1% 
(−55·5 to 
−46·9)
124 049 
(111 394 to 
137 303)
49 039 (41 
770 to 56 
227)
−60·5% 
(−64·8 
to 
−56·0)
−51·3% 
(−56·3 to 
−46·4)
  No handwashing
  with soap
1010 (798 
to 1204)
517 (408 to 
621)
−48·9% 
(−53·7 
to 
−43·8)
−45·0% 
(−49·8 to 
−40·2)
70 389 (55 
414 to 84 
417)
30 721 (24 
281 to 37 
626)
−56·4% 
(−60·9 
to 
−51·6)
−46·1% 
(−51·3 to 
−40·5)
  Air pollution 4808 (4459 
to 5157)
5527 (5109 
to 5944)
14·8% 
(5·8 to 
25·3)
−8·0% 
(−15·0 to 
−0·2)
157 831 
(145 269 to 
171 007)
141 456 
(130 071 to 
153 652)
−10·5% 
(−17·4 
to −2·8)
−12·7% 
(−19·2 to 
−5·7)
  Ambient particulate
  matter pollution
2238 (2154 
to 2317)
2926 (2777 
to 3066)
30·7% 
(25·2 to 
36·5)
2·9% (0·7 to 
5·1)
68 120 (64 
972 to 71 
405)
69 673 (65 
585 to 73 
552)
2·3% 
(−3·4 to 
8·2)
−3·0% (−6·6 
to 0·8)
  Household air
  pollution from solid
  fuels
2857 (2482 
to 3216)
2893 (2463 
to 3303)
1·3% 
(−13·4 
to 18·8)
−17·2% 
(−30·0 to 
−2·8)
101 643 
(88 877 to 
115 053)
81 087 (70 
025 to 92 
802)
−20·2% 
(−29·5 
to −9·4)
−20·4% 
(−30·5 to 
−9·1)
  Ambient ozone
  pollution
133 (105 to 
162)
217 (161 to 
272)
63·8% 
(14·5 to 
125·1)
19·8% (−16·3 
to 60·6)
3038 (2296 
to 3814)
5073 (3576 
to 6620)
66·9% 
(12·2 to 
137·1)
32·5% (−11·0 
to 84·6)
  Other environmental
 risks
731 (523 to 
965)
945 (663 to 
1279)
29·2% 
(17·1 to 
40·5)
−1·9% (−9·2 
to 4·7)
17 015 (12 
567 to 22 
173)
18 822 (13 
300 to 25 
407)
10·5% 
(0·4 to 
20·1)
−9·4% 
(−16·6 to 
−2·3)
  Residential radon 63 (41 to 
86)
92 (61 to 
128)
46·3% 
(13·1 to 
87·9)
13·8% (−11·7 
to 44·3)
1503 (984 
to 2086)
1979 (1331 
to 2768)
31·7% 
(2·4 to 
67·6)
7·1% (−17· to 
− 36·9)
  Lead exposure 668 (465 to 
899)
853 (572 to 
1181)
27·6% 
(15·1 to 
39·1)
−3·3% (−10·8 
to 3·7)
15 512 (10 
967 to 20 
727)
16 843 (11 
494 to 23 
505)
8·5% 
(−2·4 to 
18·3)
−10·9% 
(−18·9 to 
−3·8)
  Occupational risks 562 (509 to 
629)
717 (641 to 
803)
27·7% 
(13·4 to 
42·5)
4·0% (−5·7 
to 14·0)
43 879 (35 
819 to 52 
859)
55 352 (44 
589 to 67 
890)
26·2% 
(16·3 to 
36·1)
10·2% (2·9 
to 18·0)
  Occupational
  carcinogens
152 (135 to 
174)
304 (263 to 
341)
100·7% 
(78·5 to 
116·2)
52·4% (36·1 
to 63·6)
3149 (2789 
to 3543)
5803 (5076 
to 6526)
84·7% 
(66·2 to 
101·4)
48·5% (34·2 
to 60·8)
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1990 
deaths (in 
thousands)
2013 
deaths (in 
thousands)
Median 
percent 
change 
deaths
Median 
percent 
change of 
age-
standardised 
deaths PAF
1990 
DALYs (in 
thousands)
2013 
DALYs (in 
thousands)
Median 
percent 
change 
DALYs
Median 
percent 
change of 
age-
standardised 
DALYs PAF
   Occupational
   exposure to
   asbestos
94 (76 to 
116)
194 (155 to 
233)
109·6% 
(72·4 to 
132·2)
56·2% (28·9 
to 74·2)
1773 (1425 
to 2211)
3402 (2725 
to 4113)
93·4% 
(63·5 to 
117·3)
53·4% (29·9 
to 72·4)
   Occupational
   exposure to
   polycyclic
   aromatic
   hydrocarbons
3 (2 to 3) 6 (5 to 7) 120·2% 
(101·8 
to 
139·3)
71·4% (58·4 
to 85·1)
60 (51 to 
71)
125 (102 to 
146)
105·9% 
(88·3 to 
126·2)
67·4% (52·8 
to 82·7)
   Occupational
   exposure to silica
11 (10 to 
12)
21 (19 to 
24)
95·8% 
(78·9 to 
112·6)
52·8% (41·3 
to 64·1)
248 (223 to 
274)
454 (404 to 
509)
83·0% 
(67·3 to 
100·1)
49·0% (35·8 
to 61·9)
   Occupational
   exposure to
   sulphuric acid
3 (2 to 4) 4 (3 to 5) 29·6% 
(16·8 to 
48·3)
0·8% (−8·8 to 
13·1)
68 (49 to 
91)
83 (60 to 
113)
21·3% 
(9·6 to 
40·5)
−1·5% (−11·6 
to 12·1%)
   Occupational
   exposure to
   trichloroethylene
0 (0 to 0) 0 (0 to 0) 100·2% 
(88·5 to 
112·2)
54·3% (46·1 
to 62·7)
1 (0 to 2) 2 (0 to 3) 88·5% 
(77·3 to 
100·2)
51·7% (42·9 
to 61·1)
   Occupational
   exposure to
   arsenic
2 (2 to 3) 4 (3 to 4) 72·7% 
(56·4 to 
90·8)
34·7% (23·4 
to 46·8)
47 (38 to 
58)
76 (60 to 
94)
61·3% 
(46·0 to 
79·3)
31·3% (18·6 
to 44·9)
   Occupational
   exposure to
   benzene
2 (1 to 2) 3 (2 to 3) 66·2% 
(57·2 to 
75·5)
32·3% (25·8 
to 37·8)
59 (51 to 
68)
95 (81 to 
108)
59·4% 
(50·3 to 
69·1)
36·8% (29·1 
to 44·4)
   Occupational
   exposure to
   beryllium
0 (0 to 0) 0 (0 to 0) 44·3% 
(30·6 to 
62·7)
12·6% (3·0 to 
25·3)
2 (2 to 3) 3 (3 to 4) 34·7% 
(21·6 to 
53·2)
9·1% (−2·0 to 
22·3%)
   Occupational
   exposure to
   cadmium
0 (0 to 0) 1 (1 to 1) 116·6% 
(97·0 to 
137·4%)
68·6% (54·9 
to 82·2)
8 (7 to 9) 16 (13 to 
19)
102·8% 
(84·4 to 
123·2)
64·9% (49·7 
to 80·1)
   Occupational
   exposure to
   chromium
1 (1 to 1) 3 (2 to 3) 116·2% 
(96·7 to 
136·7)
68·3% (54·8 
to 81·4)
28 (25 to 
32)
57 (50 to 
65)
102·3% 
(83·8 to 
123·6)
64·6% (48·9 
to 80·4)
   Occupational
   exposure to diesel
   engine exhaust
17 (15 to 
20)
37 (32 to 
43)
116·6% 
(99·4 to 
134·9)
69·1% (57·2 
to 81·3)
394 (343 to 
449)
797 (690 to 
913)
102·0% 
(84·6 to 
120·8)
64·4% (50·5 
to 78·5)
   Occupational
   exposure to
   second-hand
   smoke
19 (17 to 
20)
34 (31 to 
37)
80·5% 
(66·8 to 
94·8)
40·6% (31·5 
to 50·0)
431 (393 to 
465)
725 (660 to 
794)
68·1% 
(54·7 to 
83·8)
36·7% (26·0 
to 48·3)
   Occupational
   exposure to
   formaldehyde
1 (0 to 1) 1 (1 to 1) 51·1% 
(34·2 to 
67·8)
20·9% (9·3 to 
32·2)
20 (16 to 
25)
29 (23 to 
35)
43·3% 
(26·9 to 
59·7)
21·3% (8·6 to 
34·3)
   Occupational
   exposure to
   nickel
6 (4 to 8) 12 (9 to 16) 103·0% 
(82·2 to 
123·6)
58·0% (42·7 
to 73·1)
135 (103 to 
173)
257 (193 to 
326)
90·5% 
(70·8 to 
110·7)
54·6% (38·4 
to 71·0)
  Occupational
  asthmagens
63 (48 to 
93)
52 (42 to 
70)
−18·4% 
(−32·9 
to 5·2)
−34·2% 
(−46·8 to 
−17·1)
2903 (2310 
to 3909)
2771 (2227 
to 3521)
−4·7% 
(−18·1 
to 12·0)
−18·1% 
(−30·5 to 
−4·4)
  Occupational
  particulate matter,
  gases, and fumes
197 (161 to 
236)
205 (164 to 
251)
3·7% 
(−7·6 to 
17·6)
−18·8% 
(−26·7 to 
−9·9)
7212 (5877 
to 8545)
8802 (7012 
to 10 740)
22·0% 
(10·9 to 
34·0)
−0·6% (−8·4 
to 8·0)
  Occupational noise .. .. .. .. 5039 (3268 
to 7193)
7119 (4549 
to 10 329)
41·4% 
(33·9 to 
48·0)
21·4% (15·1 
to 27·8)
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1990 
deaths (in 
thousands)
2013 
deaths (in 
thousands)
Median 
percent 
change 
deaths
Median 
percent 
change of 
age-
standardised 
deaths PAF
1990 
DALYs (in 
thousands)
2013 
DALYs (in 
thousands)
Median 
percent 
change 
DALYs
Median 
percent 
change of 
age-
standardised 
DALYs PAF
  Occupational
  injuries
151 (122 to 
197)
159 (127 to 
206)
4·4% 
(−24·6 
to 49·2)
−4·7% (−32·6 
to 34·2)
9776 (7809 
to 12 884)
9947 (7886 
to 12 927)
1·3% 
(−26·0 
to 42·5)
−2·9% (−29·9 
to 34·2)
  Occupational
  ergonomic factors
.. .. .. .. 15 944 (10 
747 to 22 
276)
21 109 (14 
206 to 29 
304)
32·2% 
(28·0 to 
37·7)
16·2% (11·2 
to 21·8)
Behavioural risks 18 453 (17 
419 to 19 
480)
21 909 (20 
446 to 23 
383)
18·7% 
(14·5 to 
23·1)
−0·7% (−2·4 
to 1·0)
799 073 
(753 589 to 
844 178)
717 608 
(667 831 to 
771 924)
−10·2% 
(−14·1 
to −6·1)
−7·4% (−9·8 
to −5·1)
  Child and maternal
 malnutrition
4254 (3937 
to 4555)
1665 (1487 
to 1840)
−60·8% 
(−65·0 
to 
−57·1)
−50·5% 
(−55·9 to 
−45·5)
403 951 
(371 608 to 
432 910)
176 859 
(156 431 to 
199 831)
−56·1% 
(−60·6 
to 
−52·2)
−43·2% 
(−47·9 to 
−38·9)
  Childhood
  undernutrition
3635 (3341 
to 3888)
1327 (1169 
to 1481)
−63·4% 
(−67·6 
to 
−59·6)
−53·2% 
(−58·6 to 
−48·1)
317 851 
(292 419 to 
339 549)
119 802 
(106 565 to 
133 359)
−62·2% 
(−66·3 
to 
−58·5)
−49·9% 
(−55·1 to 
−45·0)
   Childhood
   underweight
1080 (886 
to 1288)
386 (309 to 
463)
−64·2% 
(−70·5 
to 
−57·9)
−54·0% 
(−62·1 to 
−45·8)
95 709 (79 
446 to 113 
315)
35 806 (29 
108 to 42 
575)
−62·5% 
(−68·9 
to 
−56·3)
−50·2% 
(−58·3 to 
−42·4)
   Childhood
   wasting
3295 (2802 
to 3696)
1247 (1034 
to 1413)
−62·0% 
(−66·5 
to 
−57·4)
−51·4% 
(−57·1 to 
−45·2)
288 145 
(246 038 to 
322 526)
112 350 
(94 437 to 
127 169)
−60·9% 
(−65·4 
to 
−56·3)
−48·2% 
(−53·8 to 
−42·2)
   Childhood
   stunting
848 (474 to 
1339)
218 (107 to 
389)
−74·6% 
(−79·5 
to 
−68·9)
−67·3% 
(−73·9 to 
−60·0)
73 355 (40 
848 to 115 
668)
19 291 
(9581 to 34 
208)
−73·9% 
(−79·0 
to 
−68·6)
−65·4% 
(−72·2 to 
−58·1)
  Suboptimal
  breastfeeding
1344 (904 
to 1834)
501 (318 to 
697)
−62·8% 
(−67·5 
to 
−58·0)
−52·1% 
(−58·3 to 
−45·5)
116 801 
(78 740 to 
158 958)
44 203 (28 
205 to 61 
650)
−62·3% 
(−66·8 
to 
−57·6)
−49·6% 
(−55·7 to 
−43·4)
   Non-exclusive
   breastfeeding
1155 (743 
to 1606)
442 (264 to 
641)
−61·9% 
(−66·8 
to 
−56·9)
−50·7% 
(−57·3 to 
−43·9)
99 927 (64 
457 to 138 
645)
38 502 (23 
037 to 55 
565)
−61·7% 
(−66·5 
to 
−56·7)
−48·7% 
(−55·1 to 
−42·1)
   Discontinued
   breastfeeding
191 (65 to 
349)
59 (20 to 
110)
−69·3% 
(−74·6 
to 
−63·0)
−60·5% 
(−67·3 to 
−52·5)
17 046 
(5804 to 31 
059)
5722 (1898 
to 10 599)
−66·6% 
(−71·7 
to 
−60·5)
−55·4% 
(−62·1 to 
−47·6)
  Iron deficiency 241 (169 to 
344)
199 (137 to 
275)
−17·1% 
(−33·7 
to −0·5)
−21·8% 
(−35·6 to 
−7·7)
53 019 (38 
674 to 71 
446)
44 651 (31 
844 to 62 
304)
−15·6% 
(−21·5 
to 
−11·5)
−6·5% (−11·3 
to −2·0)
  Vitamin A
  deficiency
377 (247 to 
522)
85 (51 to 
125)
−77·4% 
(−82·9 
to 
−71·5)
−71·0% 
(−78·2 to 
−63·7)
32 920 (21 
694 to 45 
629)
7875 (4758 
to 11 541)
−76·1% 
(−81·6 
to 
−70·3)
−68·3% 
(−75·6 to 
−60·9)
  Zinc deficiency 221 (15 to 
491)
66 (4 to 
153)
−70·1% 
(−76·3 
to 
−62·7)
−61·2% 
(−69·8 to 
−52·4)
19 188 
(1816 to 41 
961)
5996 (745 
to 13 267)
−68·4% 
(−74·4 
to 
−56·7)
−57·3% 
(−66·1 to 
−42·6)
  Tobacco smoke 5229 (4816 
to 5681)
6149 (5587 
to 6762)
17·8% 
(10·9 to 
23·9)
−9·6% 
(−13·2 to 
−6·3)
142 341 
(131 399 to 
153 920)
143 512 
(129 979 to 
159 147)
0·7% 
(−5·5 to 
7·5)
−14·5% 
(−18·9 to 
−10·2)
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1990 
deaths (in 
thousands)
2013 
deaths (in 
thousands)
Median 
percent 
change 
deaths
Median 
percent 
change of 
age-
standardised 
deaths PAF
1990 
DALYs (in 
thousands)
2013 
DALYs (in 
thousands)
Median 
percent 
change 
DALYs
Median 
percent 
change of 
age-
standardised 
DALYs PAF
  Smoking 4634 (4222 
to 5079)
5818 (5258 
to 6435)
25·7% 
(17·9 to 
32·6)
−5·1% (−9·3 
to −1·3)
115 910 
(105 383 to 
127 110)
134 196 
(120 872 to 
149 759)
15·8% 
(8·6 to 
23·6)
−7·4% (−12·4 
to −2·2)
  Second hand smoke 595 (540 to 
654)
331 (308 to 
355)
−44·4% 
(−48·2 
to 
−40·0)
−50·9% 
(−53·6 to 
−48·2)
26 431 (22 
494 to 30 
676)
9316 (8417 
to 10,277)
−64·7% 
(−68·3 
to 
−60·8)
−60·2% 
(−63·3 to 
−56·9)
  Alcohol and drug use 2092 (1671 
to 2438)
3163 (2537 
to 3656)
51·3% 
(44·3 to 
58·4)
19·4% (15·3 
to 23·7)
89 844 (76 
788 to 101 
767)
126 053 
(107 154 to 
142 356)
40·2% 
(34·8 to 
46·3)
23·5% (18·9 
to 28·3)
  Alcohol use 1977 (1555 
to 2329)
2786 (2146 
to 3287)
40·9% 
(33·2 to 
47·9)
11·1% (6·9 to 
14·8)
76 029 (63 
443 to 87 
186)
99 278 (81 
295 to 113 
616)
30·5% 
(23·9 to 
37·0)
13·6% (8·6 to 
18·1)
  Drug use 132 (109 to 
155)
429 (381 to 
480)
224·8% 
(188·0 
to 
273·4)
179·5% 
(147·0 to 
222·3)
14 481 (11 
607 to 17 
286)
28 578 (24 
505 to 33 
104)
97·4% 
(83·2 to 
114·8)
89·3% (74·3 
to 107·1)
  Dietary risks 8068 (6991 
to 9159)
11 274 
(9656 to 12 
957)
39·6% 
(34·1 to 
46·2)
2·9% (0·3 to 
5·8)
177 408 
(154 661 to 
200 097)
241 351 
(209 634 to 
273 339)
35·9% 
(29·8 to 
43·0)
7·7% (4·1 to 
12·0)
  Diet low in fruits 2540 (1686 
to 3367)
3413 (2207 
to 4546)
33·9% 
(25·6 to 
43·3)
0·1% (−5·2 to 
5·9)
58 710 (39 
575 to 76 
928)
74 797 (49 
434 to 98 
791)
27·0% 
(19·0 to 
36·0)
1·7% (−3·8 to 
7·9)
  Diet low in
  vegetables
1381 (1094 
to 1684)
1782 (1405 
to 2173)
28·9% 
(22·3 to 
36·6)
−4·8% (−9·4 
to −0·1)
31 283 (24 
692 to 38 
039)
39 176 (31 
050 to 47 
658)
25·2% 
(17·9 to 
33·2)
−0·4% (−5·4 
to 5·1)
  Diet low in whole
  grains
1396 (1066 
to 1728)
2049 (1575 
to 2525)
46·8% 
(40·8 to 
54·2)
9·2% (5·9 to 
13·1)
34 807 (26 
736 to 43 
078)
51 411 (39 
500 to 63 
286)
47·6% 
(40·9 to 
56·0)
18·0% (13·9 
to 22·9)
  Diet low in nuts and
  seeds
1012 (725 
to 1304)
1195 (816 
to 1578)
17·7% 
(10·5 to 
25·0)
−13·3% 
(−18·7 to 
−8·5)
23 434 (16 
643 to 30 
134)
27 109 (18 
408 to 36 
030)
15·3% 
(8·0 to 
22·8)
−8·5% (−13·7 
to −3·3)
  Diet low in milk 66 (19 to 
111)
105 (30 to 
177)
58·1% 
(51·9 to 
63·8)
18·4% (14·6 
to 22·2)
1515 (434 
to 2538)
2218 (633 
to 3713)
46·3% 
(39·8 to 
52·5)
17·2% (12·6 
to 21·6)
  Diet high in red
  meat
62 (55 to 
70)
102 (89 to 
116)
64·1% 
(52·8 to 
75·8)
23·0% (14·4 
to 32·0)
2201 (1854 
to 2585)
4147 (3349 
to 5026)
88·2% 
(75·9 to 
101·6)
50·7% (41·9 
to 60·4)
  Diet high in
  processed meat
457 (332 to 
622)
644 (467 to 
881)
41·4% 
(24·1 to 
57·9)
4·4% (−8·6 to 
17·1)
11 745 
(8676 to 15 
897)
17 380 (12 
677 to 23 
925)
47·9% 
(30·9 to 
64·0)
17·3% (3·4 to 
29·4)
  Diet high in
  sugar-sweetened
  beverages
60 (44 to 
82)
126 (96 to 
166)
110·1% 
(88·7 to 
141·4)
64·4% (45·7 
to 87·2)
2712 (2006 
to 3635)
6190 (4665 
to 8142)
128·4% 
(105·4 
to 
159·0)
89·6% (70·2 
to 115·3)
  Diet low in fibre 716 (587 to 
853)
1009 (817 
to 1207)
40·6% 
(25·3 to 
60·0)
4·2% (−7·4 to 
18·0)
16 395 (13 
496 to 19 
433)
22 098 (17 
996 to 26 
349)
35·0% 
(18·6 to 
52·4)
7·4% (−5·1 to 
20·6)
  Diet suboptimal in
  calcium
85 (74 to 
97)
141 (122 to 
160)
64·6% 
(53·6 to 
80·4)
22·9% (15·2 
to 33·1)
1870 (1605 
to 2143)
2876 (2507 
to 3258)
53·5% 
(42·8 to 
66·9)
22·9% (15·5 
to 33·0)
  Diet low in seafood
  omega-3 fatty acids
712 (530 to 
909)
1031 (769 
to 1304)
44·6% 
(35·3 to 
57·3)
7·5% (1·9 to 
14·3)
16 285 (12 
321 to 20 
657)
22 448 (16 
887 to 28 
205)
37·6% 
(27·7 to 
52·7)
10·1% (2·8 to 
19·8)
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1990 
deaths (in 
thousands)
2013 
deaths (in 
thousands)
Median 
percent 
change 
deaths
Median 
percent 
change of 
age-
standardised 
deaths PAF
1990 
DALYs (in 
thousands)
2013 
DALYs (in 
thousands)
Median 
percent 
change 
DALYs
Median 
percent 
change of 
age-
standardised 
DALYs PAF
  Diet low in
  polyunsaturated
  fatty acids
447 (404 to 
493)
581 (512 to 
651)
29·6% 
(16·9 to 
44·7)
−4·5% (−13·7 
to 5·2)
10 033 
(9051 to 11 
040)
12 670 (11 
103 to 14 
342)
25·9% 
(13·0 to 
41·8)
0·0% (−9·8 to 
11·6)
  Diet high in trans
  fatty acids
464 (311 to 
650)
405 (218 to 
645)
−15·0% 
(−34·0 
to 3·7)
−38·3% 
(−52·2 to 
−24·5)
10 644 (7 
131 to 14 
859)
9875 (5503 
to 15 228)
−8·5% 
(−29·0 
to 9·6)
−28·7% 
(−43·6 to 
−14·7)
  Diet high in sodium 2562 (1377 
to 4041)
3689 (2028 
to 5810)
44·1% 
(33·8 to 
57·1)
7·4% (1·3 to 
15·5)
54 620 (29 
271 to 86 
008)
74 327 (40 
615 to 116 
717)
36·2% 
(26·5 to 
48·7)
8·4% (1·5 to 
17·5)
  Sexual abuse and
 violence
163 (141 to 
188)
257 (203 to 
312)
57·5% 
(30·6 to 
83·7)
36·7% (14·9 
to 58·9)
15 133 (12 
297 to 18 
621)
21 290 (16 
743 to 26 
065)
40·6% 
(26·4 to 
55·7)
31·8% (19·1 
to 46·0)
  Childhood sexual
  abuse
64 (53 to 
78)
68 (55 to 
82)
5·9% 
(−9·3 to 
19·9)
−7·4% (−21·4 
to 3·9)
6896 (5364 
to 8667)
7682 (5910 
to 9736)
11·4% 
(4·0 to 
18·8)
5·8% (−1·6 to 
12·6)
  Intimate partner
  violence
106 (86 to 
130)
197 (146 to 
251)
85·9% 
(49·6 to 
124·8)
60·9% (30·5 
to 93·6)
9009 (7076 
to 11 440)
14 454 (11 
027 to 18 
164)
60·6% 
(39·6 to 
85·1)
48·8% (29·3 
to 71·7)
  Unsafe sex 679 (561 to 
827)
1481 (1383 
to 1621)
118·8% 
(86·2 to 
158·1)
100·5% 
(76·6 to 
129·3)
39 761 (30 
789 to 52 
320)
73 282 (67 
015 to 82 
478)
86·1% 
(51·7 to 
127·0)
97·6% (68·3 
to 131·3)
  Low physical activity 1489 (1257 
to 1741)
2182 (1858 
to 2555)
46·5% 
(40·9 to 
52·9)
6·4% (4·0 to 
9·2)
31 247 (26 
556 to 36 
521)
45 143 (38 
328 to 52 
671)
44·3% 
(37·2 to 
52·8)
13·6% (9·4 
to 18·3)
Metabolic risks 10 398 
(9811 to 11 
003)
15 723 (14 
719 to 16 
767)
51·2% 
(46·2 to 
57·0)
10·6% (8·8 
to 12·6)
250 957 
(233 711 to 
267 582)
373 817 
(343 978 to 
403 889)
48·9% 
(43·1 to 
54·9)
18·4% (15·3 
to 21·7)
  High fasting plasma
 glucose
2444 (2101 
to 2853)
4014 (3499 
to 4641)
64·4% 
(56·3 to 
73·4)
21·8% (17·4 
to 26·8)
68 903 (60 
506 to 78 
071)
116 893 
(101 592 to 
133 368)
69·6% 
(60·9 to 
78·7)
37·0% (31·6 
to 42·6)
 High total cholesterol 2204 (1574 
to 3126)
2830 (1966 
to 4053)
28·0% 
(19·9 to 
37·4)
−7·4% (−11·3 
to −2·5)
49 289 (38 
075 to 63 
764)
62 715 (49 
244 to 80 
986)
26·9% 
(19·8 to 
36·3)
−0·6% (−5·7 
to 5·7)
 High systolic blood
 pressure
6949 (6182 
to 7665)
10 364 
(9178 to 11 
544)
49·1% 
(43·2 to 
55·2)
8·8% (6·4 to 
11·2)
143 434 
(130 053 to 
156 023)
208 129 
(188 307 to 
227 509)
45·1% 
(38·7 to 
52·1)
14·1% (10·0 
to 18·4)
 High body-mass
 index
2724 (2263 
to 3187)
4444 (3716 
to 5169)
63·2% 
(57·8 to 
69·5)
22·2% (19·0 
to 25·4)
78 310 (65 
436 to 92 
006)
134 048 
(112 420 to 
156 787)
71·3% 
(64·4 to 
78·0)
36·3% (32·3 
to 40·1)
 Low bone mineral
 density
176 (164 to 
198)
334 (285 to 
361)
92·1% 
(62·8 to 
104·0)
35·4% (15·4 
to 44·6)
10 903 
(8958 to 13 
231)
14 249 (11 
658 to 17 
500)
30·6% 
(20·9 to 
40·7)
−1·8% (−9·4 
to 6·9)
 Low glomerular
 filtration rate
1310 (1176 
to 1480)
2164 (1960 
to 2387)
65·6% 
(54·5 to 
74·5)
18·9% (11·1 
to 24·8)
34 159 (30 
499 to 38 
394)
51 906 (46 
246 to 57 
573)
52·0% 
(43·5 to 
59·3)
25·5% (18·4 
to 31·3)
DALYs=disability-adjusted life-years. PAF=population attributable fraction.
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